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ABSTRACT 
Skeletal muscle is the largest body organ comprising approximately 40% of total body weight 
under normal conditions; it is not only important for movement and posture but also for 
thermogenesis and metabolism. In fact this organ is also responsible for 70–75% of the insulin 
stimulated glucose uptake; part of the energy obtained from glucose is used to fuel muscles 
and the remaining is stored as glycogen. The effect of vitamin A metabolites including all 
trans retinoic acid (atRA), have been shown to be involved not only in skeletal muscle 
differentiation, but also in the skeletal muscle metabolism, enhancing glucose uptake, 
increasing lipid oxidation capacity and activating of PI3K-AKT pathway. However, the 
specific signaling pathway involved in retinoic acid signaling is still not completely 
understood. 
SRP-35 is a short-chain dehydrogenase/reductase belonging to the DHRS7C dehydrogenase/ 
reductase family 7, which use retinol as substrate to produce all-trans-retinaldehyde. In my 
thesis I will show that the over-expression of SRP-35 enzyme in mouse skeletal muscles 
enhances muscle performance in vivo; this effect is not related to alterations in excitation-
contraction coupling but rather is linked to enhanced glucose metabolism. Over-expression of 
this enzyme causes increased phosphorylation of AKTS473, triggering translocation of Glut4 to 
the sarcolemma and higher glucose uptake into the muscles. I will also demonstrate that 
pharmacological application of atRA, a downstream product of the enzymatic activity of SRP-
35, to intact muscles from WT mice, mimics the stimulation of AKTS473 phosphorylation 
observed in SRP35TG muscles, while inhibitors of the Retinoic Acid Receptor (RAR) α and 
RARγ nuclear receptors inhibit AKTS473 phosphorylation in muscles from WT mice treated 
with pharmacological concentrations of atRA. These results indicate that SRP-35 signaling 
involves non-genomic effects of RARα and RARγ. My results also demonstrate that RA 
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signaling affects the activation of PI3K. Skeletal muscles from SRP35TG mice showed a 14 
fold increase of PIP3 content, indicating the evolvement of Phosphoinositide 3-kinase (PI3K) 
and Mammalian target of rapamycin complex 2 (mTORC2). Additionally, the skeletal 
muscles obtained from SRP35TG mice kept under Low vitamin A diet (LVAD) for two 
generations show higher fatigue resistance and larger glycogen stores compared to those of 
WT littermates fed with the same diet. These results indicate that SRP-35 affects skeletal 
muscle metabolism and fatigue performance, which may represent an important target for the 
treatment of metabolic diseases. 
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CHAPTER 1- INTRODUCTION 
1.1 Skeletal muscle.  
1.1.1 Skeletal muscle structure and function. 
The skeletal muscle represents the principal organ of the locomotor system. It is able to 
contract longitudinally producing tension that helps the partial or complete mobility of the 
organism. The movement of this organ is mostly under voluntary control (but some skeletal 
muscles are involuntarily controlled, such as the diaphragm and extraocular muscles), while 
the activation and speed of contraction is highly regulated and is controlled by electrical 
stimuli originating in the somatic nervous system. Aside muscle fibres, additional components 
make up the skeletal muscle tissue including blood vessels, nerve fibres and connective tissue 
that all work together to facilitate coordinated movements that convey locomotion and 
stability to the whole body. An important function of skeletal muscle is also its contribution to 
the maintenance of body temperature and metabolic homeostasis, by generating heat and 
regulating glucose metabolism. The heat generated by active muscle is the result of the 
breakdown of ATP molecules during physical activity and is essential to maintain a stable 
body temperature, for example by promoting shivering-dependent thermogenesis. On the 
other hand about 80% of insulin-stimulated glucose metabolism is under control of skeletal 
muscles. The glucose that is not readily metabolized is stored as glycogen, principally in 
skeletal muscles, making this organ the largest glycogen store of mammalian organisms 
(DeFronzo et al., 1981; Hopkins, 2006; Frontera and Ochala, 2015; Drum et al., 2016). 
The skeletal muscle is generally attached to bones by tendons and cartilage or through direct 
contact and is also defined as striated for its typical striped microscopic appearance. The 
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striations are a consequence of the ordered and regular arrangement of the sub-cellular 
contractile elements (Drum et al., 2016).  
The skeletal muscle is made up of several specialized layers, structured in fascicles, muscle 
fibres, myofibrils and sarcomeres, as is shown in the figure 1.1. Specifically, the fascicle is 
defined as a bundle of muscle fibres bound together and surrounded by a layer of connective 
tissue (known as perimysium). The muscle fibres on the other hand, are multinucleated cells, 
able to contract once they receive an electrochemical stimulus in the neuromuscular junction, 
released by neurons belonging to the central nervous system. The diameter and length of 
fibres can vary enormously depending on the muscle location and animal species. In mouse, 
the soleus muscle fibres present a diameter of 47 µm and a length of 8.1 mm, while in humans 
the sartorius muscle fibres can have a diameter of 100 µm and a length up to 200 mm. The 
plasma membrane that protects the muscle fibre is calls sarcolemma and a layer of connective 
tissue composed of collagen and reticular fibres (endomysium) surrounds this membrane. The 
cytoplasm (sarcoplasm or myoplasm) of muscle fibres contains a specialized endoplasmic 
reticulum called sarcoplasmic reticulum (SR), which is involved in the storage, release and 
reuptake of calcium ions (Ca
2+
) during the excitation-contraction (ECC) coupling process. 
The myofibrils are the internal muscle fibre structures that make muscle contraction possible. 
There are hundreds of thousands of myofibrils in a single muscle fibre, and when the 
myofibrils contract the whole muscle fibre contracts. Myofibrils present an elongated shape 
that runs the length of the fibre, only connected to the sarcomere at the extremes of the fibre 
(see figure 1.1). Each myofibril is composed of thousands of sarcomeres, each having a length 
of 2 µm. These small structures (sarcomeres) have been defined as the basic functional 
contractile unit, made up by two principal proteins, actin and myosin. The actin proteins are 
attached to the border of the sarcomere in a structure called Z-discs and due to their elongated 
shape and thinner diameter (compared to myosin) are call thin filaments. The actin filaments 
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are located from the Z disc to the center of the sarcomere, where the myosin filaments (thick 
filaments) are located. These two proteins (actin and myosin) are the principal players 
involved in muscle contraction, presenting both an elongated shape and longitudinal 
arrangement that facilitate the sliding past one another that causes the contraction of the 
sarcomere. Specifically, in resting conditions the tropomyosin I protein blocks the binding of 
myosin to actin, inhibiting the two filamentous proteins from sliding past one another and 
therefore impeding sarcomere contraction. When Ca
2+
 is released to the myoplasm during an 
ECC event, this ion binds the troponin in its Ca
2+
 binding site, inducing its conformational 
…… 
 
 
… 
 
 
 
 
.. 
Figure 1.1 Schematic representation of the structure of skeletal muscle showing its 
internal components. The figure shows internal structures of the skeletal muscles including, 
fasicles, muscle fibre sarcomeres and myofilaments. (June, 2007, retrieved from 
https://humananatomy-libs.com/gross-anatomy-of-the-skeletal-muscles2/)  
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ECC event, this ion binds the troponin in its Ca
2+
 binding site, inducing its conformational 
change that shifts the position of tropomyosin and moves it away from the myosin-actin 
binding sites. Once the inhibition of the tropomyosin on the actin-myosin proteins is removed, 
the actin and the globular heads of myosin come into contact, forming a cross-bridge between 
the two proteins. Myosin hydrolyze ATP molecules and obtain the energy to move the head 
groups along the actin filaments and slide the thin and tick filaments past one another, causing 
the contraction of the sarcomere and of the whole muscle fibre (See figure 1.1 and figure 1.3) 
(Hegarty and Hooper, 1971; Burkholder et al., 1994; Harris et al., 2005; Treves et al 2009; 
Marini and Veicsteinas, 2010; Frontera and Ochala, 2015; MacIntosh et al., 2015). 
1.1.2 Skeletal muscle and fibre type composition. 
The skeletal muscle is a very plastic tissue, responding to the different needs of the organism, 
for example it allows the body to have explosive fast movements for short periods of time 
(like in the 100 m sprint race) or slow and long lasting movements (like in a marathon race). 
One of the principal keys underlying  this plasticity is the presence of different types of 
myosin heavy chain isoforms (MyHC), giving different metabolic characteristics, contractile 
speed and cellular Ca
2+
 handling characteristics to the muscle fibres (Westerblad et al., 2010). 
Based on these important characteristics, skeletal muscle fibres are classified according their 
MyHC isoforms as type I, IIa, IIx and IIb. The principal characteristic of these different fibre 
types is their speed of contraction, with MyHC type I being the slowest, type IIa of 
intermediate speed and type IIx and IIb being the most rapid. A secondary but just as 
important characteristic observed in different fibre types is their expression of proteins related 
to metabolism and Ca
2+
 homeostasis. In fast type II fibres, where the rate of cross-bridged 
cycling and ATP consumption is higher, the expression of the SR Ca
2+
 ATPase pump SERCA 
1 isoform (a major ATP consuming Ca
2+
 pump) is observed at a high density, on the other 
15 
 
hand in slow type I fibres, the SERCA isoform that is expressed is type 2 and is found at a 
lower density (Bottinelli and Reggiani, 2000). Furthermore, parvalbumin an important protein 
involved in Ca
2+
 homeostasis is almost exclusively expressed in fast fibres and almost not at 
all in slow fibres (Füchtbauer et al., 1991) whereas fast fibres express exclusively the low 
affinity high capacity calcium binding protein isoform calsequestrin 1, For their part, slow 
fibres express in addition to calsequestrin 1 also calsequestrin 2, the isoform which is also 
expressed in cardiac cells (Biral et al., 1992; Mosca et al., 2016). These findings can thus 
explain why the Ca
2+
 transient kinetics between different fibres types is so different, with the 
Ca
2+ 
kinetics of type I and IIa fibres being slower, with a wider Ca
2+
 transient of smaller 
amplitude compared to that exhibited by fast type IIx and IIb fibres (Calderon et al., 2009; 
Calderon et al., 2014). 
The different types of fibres also exhibit important metabolic adaptations in response to the 
energy consumption requirements. Fast type II fibres (with a higher ATP consumption) are 
endowed with a higher anaerobic metabolism and lower oxidative capacity that allows them 
to have short explosive movements, but with a low resistance to fatigue. These fibres thus 
have few mitochondria and are typically more white in appearance. The slow type I fibres 
present a high content of mitochondria and rely heavily on aerobic metabolism and oxidative 
phosphorylation, and contain a high density of capillaries increasing their resistance to fatigue 
(Westerblad et al., 2010; Argilés et al., 2016). 
1.2 Excitation contraction coupling and calcium homeostasis in 
skeletal muscle.  
Excitation contraction coupling (ECC) is the underlying mechanism linking plasma 
membrane depolarization to muscle contraction and represents a fast communication between 
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electrical events that occur at the plasmalemma and Ca
2+
 release from the sarcoplasmic 
reticulum, SR. In eukaryotic cells, other mechanisms link membrane receptor activation to 
Ca
2+ 
release from the endoplasmic reticulum (ER) stores to the cytosol, but unlike ECC, the 
latter events are mediated by the ubiquitous second messenger inositol 1,4,5-trisphosphate 
(IP3) via activation of the IP3 receptors which are calcium channels located on the ER 
membrane. This second mechanism that involves Ca
2+ 
channels sensitive to IP3 is not 
involved in the ECC mechanism in skeletal muscle but may be involved in transcriptional 
activation (Treves et al., 2009; Taylor et al., 2014).  
In twitch skeletal muscle fibres the sequence of events known as ECC involves: (i) initiation 
and propagation of an action potential along the sarcolemma, (ii) radial distribution of the 
change in membrane potential along the transverse tubule system (T-tubule system) which 
invaginates deep into the muscle fibres, (iii) sensing of the change in membrane potential by 
the dihydropyridine receptors (DHPR) which are L-type Ca
2+
 channels, (iv) mechanical 
interaction between the DHPR and the ryanodine receptor 1 (RyR1) Ca
2+
 release channels, 
which are activated to release Ca
2+
 from the SR into the myoplasm, (v) binding of Ca
2+
 to the 
contractile apparatus leading to fibre contraction, (vi) Ca
2+
 clearance: reuptake into the SR 
mediated by the sarcoplasmatic reticulum Ca
2+
 transport ATPase (SERCA) pumps and, to a 
lesser extent, removal to the extracellular medium by activation of the Na
+
/Ca
2+ 
exchanger 
(NCX) and activation of the  plasma membrane Ca
2+
 ATPase (Rios and Pizarro, 1991; Baylor 
and Hollingworth., 2011; Calderon et al., 2014).  
1.2.1 Ca
2+
 release mechanism. 
Ca
2+
 release from the SR is the result of multiple different processes, the first one being 
sensing the electric signal coming from the nervous system, which is translated into a 
chemical signal for the motor neurons in contact with the muscle fibres, releasing 
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acetylcholine (ACh) into the neuromuscular junction. These small neurotransmitter molecules 
(ACh) bind to their receptors on the sarcolemma and cause a change in the permeability of the 
sodium (Na
+
) and potassium (K
+
) channels leading to a change in the membrane potential 
from a resting potential of -85 mV up to 100 mV.  The depolarization travels along the 
sarcolemma and enters the transverse tubules (t-tubules), which as mentioned previously are 
invaginations of the plasma membrane that reach deep into the muscle fibre and constitute the 
triad. The triad is the intracellular structure containing the ECC machinery; it is composed of 
the two membrane compartments, T-tubules containing the voltage sensor L-type calcium 
channel (DHPR) channel and the terminal cisternae on which RyR1 channels are located 
together with additional ECC-related proteins including JP-45, triadin and junctin (see figure 
1.2 and figure 1.3; Horowicz, 1961; Zorzato et al., 2000; Apostol et al., 2009; Treves et al., 
2009; Calderón et al. 2014). Once the depolarization of the sarcolemma reaches the DHPRs in 
the T-tubules, the latter undergo a conformational change that sends a signal to the RyR1, 
located on the membrane of the SR (Rios and Pizarro, 1991, Mosca et al., 2013). The DHPR 
is a macromolecular complex made up of 5 subunits including the alfa I (α1) or Cav1.1 which 
contains the pore forming unit of the complex, α2-δ1, β1a, and γ are auxiliary subunits located 
on the extracellular, intracellular, and transmembrane space, respectively (Catterall et al. 
2011; Treves et al. 2017). More detailed characteristic of these two proteins (DHPR and RyR) 
are presented later in this chapter in section 1.2.3. In skeletal muscle the Cav1.1/DHPR 
channels are arranged in groups of four (tetrads) and face the RyR1 channels in a special 
spatial organization having a checkerboard appearance (Franzini-Armstrong, 1999). The short 
distance between these two macromolecular complexes makes the transmission of an electro-
mechanical signal between them possible, triggering conformational changes in the RyRs that 
open the channels allowing the Ca
2+
 to be released into the myoplasm (Hill et al., 2009; Reyes 
y Zarain, 2006). Ca
2+
 is  
18 
 
 
Figure 1.2. Structure of a triad. Triads are composed by a T -tubule and the sarcoplasmic 
reticulum terminal cisternae. The image on the left shows an electron micrograph of a 
transversal section of a triad, (left). The image on the right shows a schematic representation 
of a triad, showing the spatial distribution of the RyR and DHPR (image on the left taken 
from ….; image on the right, modified from Protasi, 2002). 
released from the SR at a rate of 200 µmol/ms, changing the cytosolic Ca
2+
 concentration 
from 100 nM (resting condition; Williams et al., 1990) up to 20 µM (Baylor and 
Hollingworth, 2003). The Ca
2+
 in the myoplasm interacts with troponin C removing the 
inhibition of the troponin I leading to muscle contraction, see Figure 1.3 (Treves et al 2009; 
Calderon et al., 2014; MacIntosh et al., 2015). 
1.2.2 Ca
2+
 removal mechanism.  
After contraction of the muscle fibre has occurred, the Ca
2+
 removal machinery is activated, 
removing the majority of the Ca
2+
 from the myoplasm at a rate of 50 µmol/ms, and brining the 
resting Ca
2+
 concentration back to its original level (100 nM); the latter event will then lead to 
muscle relaxation. In fast fibres, two main components are involved in reducing the free Ca
2+
 
Sarcoplasmic 
 Reticulum  
T-tubule  
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concentration: the first component of the relaxation process is almost completely due to the 
action of parvalbumin and the second component involves the action of the SERCA pumps 
(Gillis et al., 1982; Hasselbach and Makinose, 1961) and the Na
+
/Ca
2+
 exchanger (NCX) 
(Balnave and Allen, 1998; Calderón et al. 2014). 
In the first milliseconds following Ca
2+
 release from the SR, the parbalbumin proteins are 
saturated with Mg
2+
, blocking their potential interaction with Ca
2+
 and allowing Ca
2+
 ions to 
interact with troponin C leading to muscle fibre contraction. However, due to the higher 
affinity of parvalbumin for Ca
2+
 compared to Mg
2+
, it then releases Mg
2+ 
and rapidly binds the 
free cytosolic Ca
2+
. This rapidly reduces the concentration of Ca
2+
 in the myoplasm, but 
without lowering it to its original basal line since the parvalbumin proteins become saturated 
with Ca
2+
. Once the Ca
2+
 concentration has been lowered, the Mg
2+
 (now present in a higher 
concentration) is able to replace the calcium ions on the parvalbumin (Klaus 1990; MacIntosh 
et al.2006).  
 The other components involved in the Ca
2+
 removal process (SERCA and  NCX) work 
together to lower the myoplasmic Ca
2+
 concentration to its resting level and re-fill the SR 
calcium stores so that the muscle fibre is then ready for another round of activation 
(MacIntosh et al.2006; Treves et al 2009). 
The SERCA pumps are enriched in the longitudinal sarcoplasmic reticulum membranes where 
they constitute almost 80% of the proteins by mass. They are endowed with a slower activity 
and thus it takes longer to remove the remaining free Ca
2+
 from the myoplasm compared to 
the speed of parvalbumin, but the activity of the SERCA pump is considered the principal 
factor in the reuptake of Ca
2+
 into the SR (Méme et al 1998). SERCA is an ATP-dependent 
protein that transports 2 molecules of Ca
2+
 per hydrolyzed ATP. SERCA proteins can adopt 
two conformational states, E1 and E2. E1 represents the structural conformation where two 
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Ca
2+
-binding sides show high affinity and are facing the myoplasm while in the E2 
conformation the two Ca
2+
-binding sides present a low affinity and face the luminal side of 
the SR. The pumping process starts when two Ca
2+
 ions and one ATP molecule bind to the 
SERCA E1 conformational state; using the energy released from the hydrolysis of ATP, the 
pump undergoes a conformational change to its E2 state. Once the two Ca
2+
 ions are released 
into the SR, the SERCA undergoes once again a conformational change and regains its E1 
conformational state, which is thermodinamically more favorable (Green et al., 1986, 
Wuytack et al., 2002). The SERCA pumps represent the main mechanism responsible for re-
filling the SR with Ca
2+
 following ECC and are the main players involved in muscle fibre 
…… 
 
 
 
 
 
 
 
 
 
Figure 1.3. Excitation-contraction coupling mechanism. Proteins involved in the release 
and uptake of calcium in skeletal muscle (Image taken from MacIntosh et al., 2015). 
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relaxation. Several proteins including phospholamban, sarcoplipin and the micropeptide 
myoregulin are involved in the fine regulation of SERCA activity (see section 1.2.3 for a 
more detailed explanation (Periasamy et al., 2017; Treves et al., 2017). 
The Na
+
/Ca
2+
 exchanger, NCX, is a transmembrane protein found in the sarcolemma of 
cardiac and skeletal muscle and is able to transport 3 sodium ions inside for each calcium ion 
transported outside the muscle cell. Under physiological conditions, when the Na
+
 
concentration is higher outside of the cell (due to the Na
+
 gradient created by the Na
+
/K
+
 
ATPase), the NCX uses the energy generated by the entry of 3 Na
+
 to remove 1 Ca
2+
 against 
its concentration gradient. Under specific physiological conditions however, the NCX can 
also operate in reverse mode, bringing Ca
2+
 in from the extracellular environment in exchange 
for Na+. This transporter plays a greater role in cardiac muscle than in the skeletal muscle, 
where its participation in Ca
2+
 clearing is relatively minor (Balnave and Allen, 1998; Iwamoto 
et al., 2007). 
1.2.3 Components of ECC in skeletal muscle.  
The proteins involved in the release and uptake of Ca
2+
 during the ECC process have been the 
topic of studies for many years. The main players of ECC are the two calcium channels RyR1 
and DHPR/Cav.1.1, but many additional proteins play an important role in regulating this 
process and participate in Ca
2+
 homeostasis.  
Ryanodine receptors (RyR).   
RyR Ca
2+
 release channels take their name from the fact that they bind the alkaloid ryanodine 
with high affinity. The functional calcium release channel is a homotetramer of around 2 MDa 
(each subunit of 565 kDa (Zorzato et al., 1990) that plays a crucial role in the mobilization of 
Ca
2+
 from the SR during ECC in muscle cells. RyRs were first identified in the SR of skeletal 
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and cardiac muscles, but have also been identified in the endoplasmic reticulum of non-
muscle cells, where they play a role in Ca
2+
 homeostasis (Treves et al., 2017). RyRs are a 
family of proteins which exist as three different isoforms, RyR1, RyR2 and RyR3, sharing an 
overall sequence homology of 65%, and being encoded by three different genes, RYR1, RYR2 
and RYR3 (Lanner et al., 2010; Ozawa, 2015). RyR1 is principally expressed in skeletal 
muscle and to a lesser extent in smooth muscle cells, some immune cells such as dendritic 
cells and B-lymphocytes, some areas of the CNS and in neurons. As mentioned in the 
previous section, in skeletal muscle its activation occurs via an electro-mechanical process 
due to its coupling to the DHPR channels (Block et al. 1988; Zorzato et al., 1990; Ottini et al., 
1996; Ozawa et al., 2009). On the other hand, RyR2 is mainly expressed in cardiac muscles 
where it is not coupled to DHPR/Cav1.2 channels but is activated by a mechanism initiated by 
depolarization-induced Ca
2+
 influx through DHPR/Cav1.2. This mechanism that activates 
RyR2 and induces Ca
2+
 release from the SR is referred to as Ca
2+
-induced Ca
2+
 release 
(CICR) (Otsu et al 1990, Treves et al., 1993; Franzini-Armstrong, 1999). Finally RyR3 is 
ubiquitously expressed, principally in brain, as well as other tissues such as skeletal, smooth 
and eye muscles, lung, kidney, ileum, uterus, bladder and esophagus. In skeletal muscle the 
expression of RyR3 appears to be developmentally regulated.. RyR3s, as RyR2, are not 
coupled to DHPR/Cav1.1 channels, a fact that suggests their indirect activation by CICR. 
(Giannini et al., 1995; Lanner et al., 2010; Sekulic-Jablanovic et al., 2015) 
RyR1 
The RyR1 was originally identified, cloned and sequenced from rabbit skeletal muscle 
(Taheshima et al. 1990.; Zorzato et al. 1990)  In humans the gene encoding RyR1 (RYR1) is 
located on chromosome 19q13.2. The structure of this channel is homotetrameric, see figure 
1.4, with each subunit having a molecular mass of 565 KDa. The topology of each subunit 
consists of a pore region formed by six transmembrane helices located within the C-terminal 
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region, representing almost 20% of the protein. On the other hand, the N-terminal region is 
made up by a large cytoplasmic region that represents 80% of the total protein (known as the 
foot region). In skeletal muscle two different special organization models have been observed 
between the RyR1 and the DHPR/Cav1.1 channels. In the first one, each DHPR/Cav1.1 
channel belonging to a tetrads (groups of 4 DHPR/Cav1.1) located on the T-tubule membrane, 
are under each foot of the RyR1s, matching all the “feet” of the RyR1 and the DHPR/Cav1.1 
… 
 
 
 
 
 
 
 
 
 
Figure 1.4 Near atomic structure of a Ryanodine receptor. A) Shows the top view of the 
3D model of the RyR, presenting the side and diagonal dimensions of this protein. B) Shows 
the side views of the 3D model of RyR, presenting the dimension in the cytoplasmic assembly 
and the transmembrane region (modified from Wei et al., 2016).  
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channels (as is shown in the figure 1.2). In the second model the RyR1 and DHPR/Cav1.1 are 
not associated, and there are in fact uncoupled RyR1. In mature skeletal muscles half of the 
RyR1 are coupled and the other half is uncoupled (Franzini-Armstrong and Nunzi, 1983; 
Zorzato et al., 1990; Franzini-Armstrong et al., 1998). 
Physiological activation of Ca
2+
 release from RyR1s occurs via an electro-mechanical 
coupling to the DHPR/Cav1.1 channel. But additionally RyR1s can also be activated by Ca
2+
 
as well as pharmacologically, with caffeine, 4-chloro-m-cresol and low concentration of 
ryanodine (˂10 µM). RyR1 are inhibited by Mg2+, higher concentrations of ryanodine (≥100 
µM) and ruthenium red (Meissner et al. 1986; Lai et al. 1989; Lanner et al., 2010). The 
activity of the calcium channel is also modulated by the interaction with calmodulin (CaM), 
S100, calsequestrin (CASQ), FK506-binding proteins (FKBPs) triadin and junctin. Mutations 
in the RYR1, the gene encoding RyR1, have been associated with several human diseases 
including the pharmacogenetic disorder malignant hyperthermia, the congenital myopathies 
central core disease, multimini core disease, centronuclear myopathy, congenital fibre type 
disproportion, heat/exercise induced exertional rhabdomyolysis and atypical periodic 
paralyses (Priori and Napolitano, 2005; Lanner et al., 2010; Treves et al., 2017). 
DHPR/Cav1.1 
The DHPRs present a molecular mass of 190-250 KDa and belong to the family of L-type 
high-voltage-activated Ca
2+
 channels; they are made up of 5 subunits of which the pore-
containing calcium channel subunit is called alfa 1 or Cav. Mammalian cells express at least 4 
Cav isoforms (Cav1.1–1.4) (Catterall). Cav1.1 and Cav1.2, are known as dihydropyridine 
receptors (DHPR), and are located principally in the skeletal and cardiac muscles, 
respectively. The α1 subunit is both the voltage sensing and the pore forming subunit, 
whereas the α2δ, β and γ are auxiliary subunits located in the extracellular, intracellular, and 
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transmembrane space, respectively (See figure 1.5). The latter subunits modulate, the 
activation and inactivation kinetics, gating properties and membrane trafficking of the α1-
subunit (Bers, 2002; Lanner et al., 2010; Treves et al., 2017).   
 
Figure 1.5 Structure of the voltage-gated Ca2+ channel Cav1.1. The cryo-EM structure of 
the Cav1.1 complex at a nominal resolution of 4.2 Å, showing the four Cav1.1 subunits (α1, 
α2δ, β and γ) with colored domains (image taken from Wu et al., 2015). 
The Cav1.1 subunit of is encoded by CACNA1S gene, mutations in this gene have been shown 
to have negative effects on skeletal muscle Ca
2+
 homeostasis.. Specifically, the presence of 
the CACNA1S p.R174W mutation induces RyR1 leak due to the alteration of the regulation of 
Cav1.1 over RyR1. The RyR1 leak causes negative effect in the muscle fibres, increasing 
resting cytosolic Ca
2+
 and partial depletion of SR Ca
2+
 stores (Treves et al., 2017). Another 
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significant aspect that was recently identified is the role of DHPR as Ca
2+
 channels. In the 
skeletal muscle the voltage-induced conformational changes of DHPRs is transmitted to 
RyR1s, which subsequently open and release Ca
2+
 to the sarcoplasm, as previously explained. 
However DHPRs are also able to transport a Ca
2+
 current, whose role in ECC is still not 
completely clear (Rios and Brum., 1987; Bannister and Beam, 2013). To clarify if DHPRs 
play important or just a vestigial role in ECC, Grabner`s group (University of Innsbruck, 
Austria) designed a DHPR pore-blocked channel, based on the non-Ca
2+
-conducting DHPRs 
from euteleost fish, to block the DHPR Ca
2+
 current in the skeletal muscle of mice (Dayal et 
al., 2017). Evaluation of muscle fibres, isolated mucle force and whole body muscle force (in 
vivo experiments) of DHPR knock-in-mice revealed no difference in SR Ca
2+
 release, 
locomotor activity, muscle strength and fatigue resistance compared to wild-type mice (Dayal 
et al., 2017). 
Calsequestrin 
The Ca
+
 sequestering protein calsequestrin (CASQ), is an SR Ca
2+
 binding/storage protein 
concentrated in the terminal cisternae of the SR. This protein was first isolated from the SR of 
rabbit; in mammalian cells CASQ is present in two isoform (1 and 2), CASQ 1 is present in 
slow and fast skeletal muscle fibres while CASQ 2 is expressed predominantly in cardiac 
muscles and to a lesser extent in slow-twitch skeletal muscle fibres (D’Adamo et al., 2016). 
CASQ1 migrates as a protein with an apparent mol weight of 60 kDa, but the cDNA sequence 
encodes a protein of 367 residues  plus a  28 residue amino-terminal signal sequence 
(MacLennan and Wong, 1971; Zarain-Herzber et al., 1988). In the SR CASQ buffers a large 
amount of Ca
2+ 
due to its low-affinity (Kd ∼ 103 M
−1
) and high Ca
2+
 binding capacity (40 mol 
Ca
2+
/mol protein at pH 7.5; Sanchez et al., 2012). When millimolar Ca
2+
 is present in the 
lumen of the SR (resting conditions), CASQ polymerizes forming long polymeric tendrils 
(also known as calcium wires) in an area adjacent to the RyR1 where it acts as the principal 
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SR Ca
2+
 storage protein (MacLennan and Wong., 1971; Treves et al., 2017). Recent in vivo 
experiments have demonstrated that CASQ is partially depolymerized when the SR Ca
2+
 
concentration decreases (conditions produced by fatigue stimulation, long-lasting 
depolarization or low drug concentrations) and is fully depolymerized when Ca
2+
 depletion is 
maximal, a condition which is achieved when the SR is treated with calcium channel opening 
drugs (Manno et al., 2017).  
SERCA 
The sarcoendoplasmic reticulum Ca
2+
 ATPase (SERCA) is a single polypeptide of 110 kDa, 
localized in the longitudinal SR membrane. This protein is widespread in both eukaryotic and 
prokaryotic cells, revealing it as a versatile and evolutionarily conserved protein (Periasamy 
and Kalyanasundara, 2007) SERCA presents a big variability in vertebrates, where three 
distinct genes encoding SERCA 1, 2, and 3, that produce 10 different isoforms through 
alternative splicing can be found. The expression of each isoform is also variable 
depending on the organ and tissue where it is expressed. SERCA1 is expressed in fast-
twitch skeletal muscle and is alternatively spliced to encode SERCA1a (adult) and 1b 
(fetal). On the other hand SERCA2 encodes SERCA2a, which is present predominantly in 
cardiac and slow-twitch skeletal muscle; SERCA2b is ubiquitously expressed but in low 
levels. Finally, SERCA3 isoform are expressed in non-muscle tissues. 
SERCA belongs to the family of P-type ATPases that includes plasma membrane Ca
2+
+ 
ATPase (PMCA), Na+/K+ ATPase, and H+, K+ ATPase. As mentioned in the previous 
section this pump utilizes the energy derived from ATP hydrolysis to transport 2 Ca
2+
 ions 
across the membrane; its activity is regulated by the small-molecular-weight proteins 
phospholamban and sarcolipin, in a tissue-specific manner. The lack of SERCA has been 
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linked to human diseases and several animal models have been generated. In Brody’s disease, 
it was demonstrated that both copies of the SERCA1 gene contain inactivating mutations; 
such patients show a skeletal muscle disorder characterized by impaired muscle relaxation, 
stiffness, and cramps (Odermatt et al., 1996). The SERCA1 KO animal models, demonstrated 
that the lack of SERCA1 causes severe impairment of the respiratory muscles with the mice 
becoming cyanotic and finally dying shortly after birth (Pan et al. 2003). SERCA2 null mice 
do not survive birth due to the principal role of this protein in cardiac and slow-twitch skeletal 
muscle (Prasad et al., 2004; Maclennan, 2004; Periasamy and Kalyanasundaram, 2007; 
Periasamy et al., 2017). 
JP-45 
JP-45 is a 45 KDa protein transmembrane protein of the SR junctional face membrane of 
skeletal muscle (Zorzato et al., 2000). Its expression is developmentally regulated, reaching 
maximal levels during the second month of post-natal development. This protein is 
phosphorylated by PKA and interacts with CASQ in the SR lumen through its luminal short 
carboxy-terminal domain. Different experiments have shown that it also interacts through its 
amino terminus with a region within the I–II loop (referred to as AID) of the Cav1.1 The 
interaction of JP-45 with CASQ and Cav1.1 hints towards the possible functional role of this 
protein (JP-45) in a signalling pathway linking CASQ and the DHPR. Over-expression and 
ablation of JP-45 affect the functional expression of Cav1.1 inducing a decrease of voltage-
dependent Ca
2+
 release. Young JP-45 KO mice, show a skeletal muscle phenotype similar to 
that observed in aged mice, with a lower membrane density of the voltage sensor (Cav1.1; 
Zorzato et al., 2000; Anderson et al. 2003; Rossi and Dirken, 2006; Treves et al., 2013; Mosca 
et al., 2016).  
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Triadin 
Triadin is a 95 kDa protein, specifically localized in the triad of skeletal muscle. Triadins are 
a family of multiple proteins, of different isoforms produced by the alternative splicing of a 
single TRDN gene. Expression of three different triadin isoforms has been observed in rat 
skeletal muscle (Trisk 95, Trisk 51 and Trisk 32 (Vassilopoulos et al., 2005). These isoforms 
present a common structure, only differentiated by the length of their luminal segment and 
their unique C-terminal domain. Trisk 95 and Trisk 51, are exclusively expressed in skeletal 
muscle, associated with RyR1 and CASQ1.  Functional in vivo studies have shown that 
triadin is able to regulate the activity of the RyR1 channel either directly or via its interaction 
with CASQ (in vivo). Trisk 32, is mainly expressed in cardiac muscle and to a lesser extent in 
skeletal muscle (Marty et al., 2009).. Studies on triadin KO mice model, showed that the mice 
have a moderate but clear skeletal muscle weakness, associated with reduction in the 
amplitude of calcium releass, and cardiac muscle abnormalities, showing arrhythmia 
following isoproterenol administration (Treves et al. 2009; Marty, 2015).  
Junctin 
Junctin is a structural protein present in cardiac and skeletal muscle junctional SR 
membranes, with a molecular weight of 26 KDa. Studies in skeletal muscle show that junctin 
belongs to the family of single membrane-spanning proteins (along with aspartyl β-
hydroxylase and junctate) that result from alternative splicing events of the same gene located 
in human chromosome 8. Junctin binds to the Ca
2+
 binding protein calsequestrin and the 
transmembrane protein triadin forming a complex in the lumen of the SR capable of 
associating and communicating with the RyR1. Studies have demonstrated that this 
quaternary complex, junctin, triadin, calsequestrin and RyR1, may be important for Ca
2+
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release during the ECC event in skeletal and cardiac muscles (Zhang et al., 1997; Treves et 
al., 2000; Treves et al., 2009) 
Parvalbumin 
Parvalbumin is a low molecular weight soluble protein of 12 KDa belonging to the large 
family of EF-hand Ca
2+
-binding proteins (Raymackers et al., 2000). It is present principally in 
fast skeletal muscle and specific nerve cells. In lower vertebrates, five parvalbumin 
isoforms have been identified, whereas in adult rodents a single isoform is expressed. Fast 
skeletal muscles from lower vertebrates and from small mammals contain high concentrations 
(0.5 mM) of parvalbumin. This protein is exclusively found in the SR, presenting a high 
selectivity for Ca
2+
 over Mg
2+
 ions. It has been estimated that, under resting conditions 
parvalbumin is essentially in the Mg-parvalbumin complex form, but during an ECC event, it 
binds myoplasmic Ca
2+
, reducing the Ca
2+
 concentration and enhancing relaxation. 
Experiments using parvalbumin (PV −/−), knockout mice show that in skeletal muscle the 
decay of intracellular Ca
2+
 concentration after 20 ms stimulation was slower compared to WT 
mice. The longer extension of the half-relaxation time in these PV −/− mice induced an 
increased in the intracellular Ca
2+
 concentration that caused a greater force (40 %) compared 
to that of WT mice (Schwaller et al., 1999; Raymackers et al., 2000; Racay et al., 2006). 
SRP-27 
Sarcoplasmic reticulum protein of 27 kDa (SRP-27) also known as mitsugumin-33 or TRIC-A 
trimeric intracellular cation-selective channel (TRIC-A) is expressed in skeletal muscle, heart 
and brain. Specifically, it is highly expressed in fast twitch skeletal muscle fibers and to a 
lesser extent in slow twitch fibres and its peak expression level occurs during the first month 
of post-natal development. This protein is composed by four transmembrane-spanning alpha 
helices and its C-terminal domain faces the cytoplasmic side of the endo(sarco)plasmic 
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reticulum. Three-dimensional reconstruction studies of the native protein suggest that it 
acquires a pyramidal elongated structure and experimental data have shown that it is a cation 
channel, with a selectivity of K
+
 over Na
+
, presenting a permeability ratio of PK/PNa= 1.5. 
SRP-27 KO mice are viable and do not present a critical change in their phenotypes, 
nevertheless they  had a reduced K
+
 permeability accompanying thapsigargin-induced Ca
2+
 
efflux (Bleunven et al., 2008; Yazawa et al., 2007; Treves et al 2009). 
 
1.3 Skeletal muscle metabolism.  
As important as skeletal muscle is for movement, using energy to produce contraction, it also 
plays an important role in metabolism and specific carrier molecules bring energy into the 
muscle in the form of glucose. Thus skeletal muscle is considered one of the main players in 
whole body metabolic homeostasis. This tissue is able to take up glucose in response to 
insulin signaling or after muscle contraction.   
1.3.1 Insulin 
Insulin is an anabolic polypeptide hormone, considered the most potent physiological 
anabolic agent known. It plays an important role in the storage and synthesis of lipids, protein, 
and carbohydrates, regulating their breakdown and release into the circulation. In humans the 
insulin gene is located on the short arm of chromosome 11 in the region p13. The atomic 
resolution structural analysis revealed that this hormone is a quaternary macromolecule, 
composed of two polypeptide chains, A and B, which are cross-linked by two disulphide 
bonds, as shown in figure 1.6 . The stability of insulin can be affected by different factors 
such as its concentration, pH and the presence of ions (principally zinc). Insulin can form 
aggregates that reduce drastically its biological activity and block the delivery routes of this 
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hormone. Such an effect could cause severe problem for patients under insulin treatment, due 
to the possible blocking effect caused by aggregates of artificial drug delivery systems 
(Bunner et al. 2014). At low insulin concentrations this polypeptide hormone exists as 
monomers and can undergo protein unfolding. The insulin peptides that lose their native 3-
dimensional structure interact with each other to form aggregates known as fibrils, reducing 
the activity of insulin. On the contrary, at high insulin concentrations (>5 mg/ml) and pH 7.4 
the insulin monomers form dimers or hexamers through their hydrophobic interaction. 
Additionally, the presence of zinc ions in a pH range 4–8, induce the assembly of insulin 
hexamers (see figure 1.6), which avoids insulin denaturation and maintains prolonged insulin 
activity (Owerbach et al., 1981; Zhang et al., 2004; Bunner et al., 2014) 
 
Figure 1.6 Insulin structure. A) 3D model of the insulin monomeric structure. B) 3D model 
of the insulin hexameric structure showing the zinc ion in the center of the hexamer (image 
modified from Nedumpully-Govindan and Feng Ding, 2015). 
Insulin induces a big effect on the whole organism, but its bigger effects are on the liver, 
brain, adipose tissue and skeletal muscle. After insulin is released into the blood stream, 
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different organs respond in a specific manner: the brain inhibits both hepatic glycogenolysis 
and lipolysis and decrease the appetite through lepting regulation; the liver increase its 
glycogen synthesis and lipogenesis and decrease the gluconeogenesis and glucose release; the 
adipose tissue increases its glucose uptake and storage, and also affects its lipid breakdown 
pathway, increasing lipogenesis and decreasing the lipolysis; finally, the skeletal muscle 
increases its glucose uptake and glycogen synthesis. Beside the strong metabolic effects of 
insulin on the organism, this hormone has also an important role in different cellular 
processes, which include protein synthesis, mitochondrial biogenesis, growth, autophagy, 
proliferation, differentiation, and migration (Filippi et al., 2013; Bunner et al., 2014).  
Insulin pathway in skeletal muscle. 
The body presents a complicated and sophisticated mechanism that regulates the glucose 
levels in the organism. After a meal, insulin that is produced by the beta cells of the pancreas 
as result of the processing of the molecular precursor proinsulin, is released into the blood 
stream, where it travels to different tissues and organs including adipose tissue, liver, skeletal 
muscle and nervous system. Skeletal muscle plays a very important role in glucose 
homeostasis, being responsible for about 80-90% of insulin-stimulated glucose uptake (Leto 
and Saltiel, 2012). 
Because of metabolic syndrome disorders and the increase in worldwide type 2 diabetes, the 
insulin pathway has become the focus of many research laboratories and its mode of action in 
muscle has been investigated in detail. After the binding of insulin to the α-subunit of the 
insulin receptor (IR), a heterotetrameric bifunctional complex composed by 2 extracellular α 
subunits and 2 transmembrane β subunits with tyrosine kinase activity, this complex (IR) 
becomes activated and one of its β subunit is trans-phosphorylated. This in turn increases the 
kinase catalytic activity of the  (IR) β subunit which phosphorylates and activates the insulin 
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receptor substrates 1 and 2 (IRS1, IRS2). These phosphorylated IRS proteins interact with 
phosphatidylinositol 3-kinase (PI3K), an important regulator of glucose homeostasis. 
Phosphatidylinositol-3,4,5-trisphosphate (PIP3) is produced by PI3K at the cytoplasmic face 
of the plasma membrane and induces the activation of 3-phosphoinositide-dependent kinase 1 
(PDK1) that phosphorylates AKT on threonine 308 (T308). For the full activation of AKT, 
phosphorylation of serine 473 (S473) is also necessary and this phosphorylation is mediated 
by the mTORC2 complex activated by PIP3. Active AKT also phosphorylates  the tre-
2/BUB2/cdc 1 domain family (TBC1D1, also known as AKT substrate of 160 kDa, AS160) 
and triggers the translocation of the Glucose transporter 4 (Glut4) to the plasma membrane, as 
shown in figure 1.7  (Leney and Tavare, 2009; Dibble and Cantley, 2015; Cartee, 2015). 
 
Figure 1.7. Insulin and muscle contraction pathways. Insulin and muscle contraction 
pathways share both AKT and AMPK, dependent phosphorylation, respectively. Both 
proteins activatedAS160 and induce the translocation of Glut4 to the sarcolemma (image from 
Röckl et al. 2008). 
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Experiments in animal models where the disruption of insulin signaling in liver, skeletal 
muscle or adipose tissue was induced using different experimental approaches, including 
genetic, pharmacological, surgical, and dietary inductions, showed severe hyperinsulinemia 
and in general leaded to the development of diabetes in these animals. Specifically, mice 
lacking whole body insulin receptors (IR) show that insulin is important for postnatal fuel 
homeostasis but not for prenatal growth and metabolic control. IR-KO newborn mice 
exhibited a slight growth retardation, but no metabolic abnormalities. After birth fast 
metabolic changes were observed, with glucose levels increasing drastically upon feeding, 
and insulin levels rising up to 1000 fold above normal. After a few days β-cell failure 
occurred and finally the animals died of diabetic ketoacidosis. On the other hand, when less 
severe approaches were taken such as mice lacking insulin receptors in specific cell types,  
different phenotypes were observed, with mice developing only mild metabolic and 
reproductive abnormalities (Kitamura et al., 2003; Zhang et al., 2004. Bunner et al., 2014).  
1.4.2 AMPK 
The AMP-activated protein kinase (AMPK) is considered one of the crucial cellular energy 
sensor proteins. The AMPK structure, as determined by X-ray crystallography, shows a 
heterotrimeric complex comprising an α-catalytic subunit and two regulatory subunits (β and 
γ), (see figure 1.8). Interestingly, genes encoding AMPK subunits are found in essentially all 
eukaryotes; in   humans there are two α-subunits, α1 and α2, encoded by the genes PRKAA1 
and PRKAA2, two β-subunits, β1 and β2, encoded by PRKAB1 and PRKAB2 and three γ-
subunits, γ1, γ2 and γ3, encoded by PRKAG1, PRKAG2 and PRKAG3 genes, respectively 
(Hardi et al., 2012). All possible combinations between these different subunits can occur, 
opening the possibility of forming 12 potential AMPK complexes. In detail, the α-subunit is 
generally structured with a conventional kinase domain at its N terminus which is 
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immediately followed by an auto-inhibitory domain (AID) and subsequently by an extended 
'linker peptide' that connects the AID to the α-subunit carboxy-terminal domain (α-CTD), see 
figure 1.8. It is important to mention that threonine residue 172 (Thr172), is located on the 
segment of the amino-terminal kinase domain of the α-subunit, and its phosphorylation 
induces AMPK activation increasing the activity of this enzyme several-hundred-fold. The β-
subunit contains a carbohydrate-binding module (CBM) which allows AMPK to associate 
with glycogen particles (the exact mechanism of this module remains uncertain, but possibly 
is may allow the co-localization of AMPK and glycogen particles). Following the CBM there 
is the β-subunit C-terminal domain (β-CTD), which interacts with the α and γ subunits. 
Finally the γ subunit, is made up of four tandem repeats of a sequence motif named after 
cystathionine β-synthase (CBS), see figure 1.8 (Xiao et al., 2011; Herzig and Shaw, 2017).  
 
Figure 1.8 Domain map of typical mammalian AMPK.  Composition of the heterotrimer 
AMPK enzyme with its α, β and γ subunits and their domain components (image from Hardi 
et al., 2012).  
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AMPK animal model have been very useful to understand the role of the different subunits 
that make up the AMPK protein. Mice lacking the AMPK α subunit 1 KO (AMPKα1−/−) in 
their skeletal muscles did not present any significant irregularity in glucose homeostasis, 
confirmed by glucose tolerance test. Conversely, AMPKα2−/− mice exhibited a clear change 
in the glucose metabolism (Viollet et al. 2003b). These mice exhibited high plasma glucose 
levels and reduced insulin sensitivity. On the other hand, studies in mice carrying single 
mutations in PRKAB1 and PRKAB2 or deletions of muscle β1 or β2 subunit, did not show 
apparent metabolic problems. Nevertheless, when both AMPK β1 and β2 isoforms where 
deleted in the skeletal muscle of mice (AMPK β1& β2−/) the animals showed physical 
inactivity and had a drastic diminished capacity for treadmill running. These problems have 
been associated with a reductions in skeletal muscle mitochondrial content and reduction in 
the contraction-stimulated glucose uptake (Viollet et al., 2003a; O'Neill, 2011). Lastly, mice 
with skeletal muscle-specific mutations in the AMPK γ1 subunit showed higher AMPK 
activation and higher muscle glycogen content (Barrét al., 2007). Moreover, transgenic mice 
with chronic γ2 AMPK activation exhibited ghrelin signaling-dependent hyperphagia, obesity, 
and impaired pancreatic islet insulin secretion. For their part, AMPK γ3 knock-out mice 
revealed that this subunit protect the skeletal muscle against excessive triglyceride 
accumulation and insulin resistance, forming heterotrimers with α2 and β2 isoforms in 
glycolytic (fast-twitch type II) skeletal muscle fibres (Barnes et al., 2004; Kim et al., 2014; 
Willows et al 2017; Yavari et al., 2017). 
Muscle contraction and AMPK 
Exercise (muscle contraction) presents two different effects on the organism’s balance of 
glucose homeostasis. The first occurs a few hours after exercise when an insulin-dependent 
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pathway is activated and induces the translocation of Glut4 onto the sarcolemma promoting a 
higher glucose uptake into the skeletal muscle. This pathway is mediated by AMPK, a protein 
that as AKT is able to activate the TBC1D1/AS160 protein. The second pathway, unlike the 
first, takes place up to 48 hours after exercise has stopped and consists in the improvement of 
whole-body insulin sensitivity (Mikines et al., 1988; Koopman et al., 2005; Jensen and 
O'Rahilly, 2017). It is thought that the absence of these two effects mediated by exercise are 
linked to different chronic conditions such as hypertension, coronary heart disease, metabolic 
syndrome, obesity, type 2 diabetes mellitus (T2DM), and age-related muscle wasting 
(sarcopenia) and can be prevented and treated with regular physical activity (Juleen and 
Zierath, 2013). 
During exercise the body regulates the rate of energy production, blood flow, and substrate 
utilization in response to high or low locomotion intensity. The liver releases up to 80 % of 
the glucose present in the blood in response to exercise-induced changes in glucagon (a 
polypeptide hormone released by pancreatic alfa cells, that actives liver glycogenolysis) and 
AMP levels. Adenosine triphosphate (ATP) is considered the “energy currency” of cells, 
since its hydrolysis provides the energy required by most biological processes; its hydrolysis 
produces adenosine diphosphate (ADP) and adenosine monophosphate (AMP), which are 
lower energy molecules. The ATP/ADP or ATP/AMP ratios are used by organisms to 
determine their energy levels, and AMPK is the protein that senses the changes in these ratios. 
Under low energy level conditions AMPK is able to switch off ATP consuming pathways 
such as fatty acid and cholesterol biosynthesis and switches on ATP generating processes 
mediated by glucose uptake and fatty acid oxidation  (Pencek et al. 2005; O'Neill, 2013). 
 Once the ATP/ADP ratio level decreases a signal is released within the cell signaling that 
more ATP is required. An allosteric mechanism triggered by the binding of ADP and AMP to 
the γ-subunit of AMPK stimulates its kinase activity, inducing the phosphorylation of Thr172 
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and also protecting this residue from being dephosphorylated by phosphatases. Upstream 
kinases LKB1 and Ca
2+
/calmodulin-dependent protein kinase kinase (CaMKK) also 
phosphorylate AMPK Thr172 stimulating its activity by an additional 100 times. LKB1 is 
activated as a result of low ATP/ADP and ATP/AMP ratios and CaMKK activation is due to 
elevated intracellular Ca
2+
, but even if both induce the phosphorylation of AMPK, recent 
studies have shown that LKB1 plays the major role in AMPK phosphorylation and in 
translocation of Glut4 to the plasma membrane. See Figure 1.7 for a detailed scheme (O'Neill, 
2013; Herzig and Shaw, 2017). 
1.4.3 Glucose transporters 
The requirement of mammalian cells for energy is supplied by sugar molecules. The transport 
of sugar is made facilitated by sugar transport proteins belonging to the family of integral 
membrane proteins called Gluts, which in turn are part of the major facilitator superfamily 
(MFS) of membrane transporters (Carruthers et al., 2009). Glut proteins catalyze 
unidirectional sugar uptake and release based on the sugar concentration gradient, from a high 
to lower sugar concentration. This “facilitated diffusion” is several orders of magnitude faster 
than sugar diffusion across artificial lipid bilayers (Carruthers et al., 2009). The Glut 
transporters present strong specificity for d-stereoisomers of pentose and hexose 
monosaccharides, including, d-glucose, d-galactose, among others.  These transporters are 
encoded by the gene SLC2A and are composed of ∼500 amino acids. They are predicted to 
possess 12 transmembrane-spanning alpha helices and a single N-linked oligosaccharide and 
depending on their sequence similarities, can be grouped into three different Glut family 
classes (Thorens and Mueckler, 2010). Class I includes the transporters Glut1 to Glut4, which 
are characterized by their specific glucose transporter function and their characteristic tissue 
specific distribution (Glut1, erythrocytes, brain microvessels; Glut2, liver, pancreatic islets; 
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Glut3, neuronal cells; Glut4, muscle, adipose tissue). Class II is composed by the fructose-
specific transporter Glut5 and three related proteins, Glut7, Glut9, and Glut11. Finally, class 
III is composed of Glut6, Glut8, Glut 10, Glut12 and HMIT1, presenting as principal 
characteristic the lack of a glycosylation site in the first extracellular linker domain and by the 
presence of such a site in loop 9 (Joost et al., 2002; Carruthers et al., 2009; Thorens and 
Mueckler, 2010). 
Glut1 
Glut1 was the first glucose transporter isoform to be identified, purified and cloned; 
subsequent to its identification it was discovered that this transported can also carry galactose 
and ascorbic acid. In humans the gene encoding Glut1 is located on chromosome 1 (1p35-
31.3; Carruthers et al., 2009). Unlike Glut4, Glut1 is always present on the plasma membrane 
and is activated by a non-insulin-sensitive pathway, even if present on the plasma membrane 
of insulin-responsive tissues. Glut1 plays an important role in insulin-non-responsive tissues 
by mediating glucose transport down its concentration gradient, mostly from the blood into 
cells (except in the intestine where glucose flows from the lumen of the cells to the 
extracellular environment). This transporter is highly expressed on the plasma membranes of 
proliferating cells forming the early developing embryo, in cells forming the blood-tissue 
barriers, in human erythrocytes and astrocytes, brain and cardiac muscle (Mann et al., 2003; 
Carruthers et al 2009) and it is cytochalasin B (IC50 = 0.44 μM), HgCl2 (IC50 = 3.5 μM), 
phloretin (IC50 = 49 μM), and phlorizin (IC50 = 355 μM) (Helgerson and Carruthers., 1987; 
Agustin, 2010). Under physiological conditions in the brain Glut1 provides the necessary 
glucose required by neurons to function and indeed glucose is the main energy source of the 
central nervous system (CNS). In human red blood cells Glut1 plays an important role as 
demonstrated by the fact that it is the only Glut isoform present and by the fact that it 
comprises 10-20 % of the integral membrane protein content. Competitive inhibition studies 
41 
 
of the substrate specificity of the Glut1 transporter have shown that hydroxyl (OH) groups at 
C1 and C3 of d-glucose serve as hydrogen bond acceptors when d-glucose is seated in the 
Glut1 sugar uptake site (heilig et al., 2003; Carruthers et al 2009; Wang et al., 2017). In 
skeletal muscle Glut1 expression is usually higher in young mice (4 weeks) and decrease in 
older mice (22 and 44 weeks). This higher expression of Glut1 in early developmental stages 
has been explained as a mechanism to ensure insulin-independent glucose transport to sustain 
the high energetic demands required during the early stages of life (Dos Santos et al. 2012). 
Glu1-deficient mice present different metabolic and non-metabolic related effects. 
Heterozygous and homozygouss Glut1-deficient mice exhibited a 50 and 95 % reduction of 
the glucose uptake rate, respectively, with the homozygous genotype being lethal for mice 
during gestation. Developmental problems were also noted in these mice, including 
intrauterine growth retardation, caudal regression, anencephaly with absence of the head, 
microphthalmia, micrognathia, and reduced body weight (embryos, ~30 % reduction in body 
weight). These developmental problems have been related to hyperglycemia of maternal 
diabetes (where glucose uptake is reduced and apoptosis is activated) caused by the exclusion 
of Glut1 during the embryonic period (Heilig et al., 2003).  
Glut4  
Glucose transporter 4, has molecular weight of 50 KDa and belongs to the 13 sugar 
transporter proteins responsible for importing glucose into the cells through a facilitated 
diffusion (ATP-independent) mechanism (Leney and Tavare, 2009). This transporter is almost 
exclusively expressed in skeletal and cardiac muscles (Kraegen et al., 1993) and brown and 
white adipose tissue, where it is responsible for most of the insulin-stimulated glucose uptake. 
The affinity of Glut4 for glucose is similar to that of (Km~5mM) and it is inhibited by 
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cytochalasin B (IC50 = 0.2 µM), Phloretin (IC50 = 10 µM), and phlorizin (IC50 = 140 µM) 
(Leney and Tavare, 2009; Agusting, 2010). 
In non-stimulated muscle fibres Glut4 is mostly stored in distinct intracellular compartments 
as Golgi complex, trans-Golgi network, lysosomes, late endosomes and recycling endosomes 
(Ralston and Ploug, 1996; Leney and Tavare, 2009) and just 5 % of this protein is present on 
the sarcolemma, but once the signal from insulin (though AKT) or muscle contraction 
(through AMPK) induces Glut4 activation, around 50 % of the total Glut4 is translocated onto 
the sarcolemma. Defects of this translocation system together with defects in insulin secretion 
and cell insulin recognition system  result in a disruption of the whole organism’s metabolism, 
giving rise to type 2 diabetes mellitus (Zisman et al., 2000; Leney and Tavare, 2009). 
Heterozygous Glut4 knockout mice show yperglycemia and hyperinsulinemia associated with 
reduced muscle glucose uptake, hypertension and morphological alterations of the heart and 
liver. Fifty percent of the mice develop diabetes by the age of 6 moths (Stenbit et al., 1997). 
Glut4 tissue-specific expression is apparently interconnected with the metabolic response of 
other tissues. Indeed, muscle-specific Glut4 deficiency in mice leads to a lower insulin 
response of adipose tissue and liver (Zisman et al., 2000); adipose-tissue specific Glut4 
depletion in mice leads to muscle and liver insulin resistance (Abel et al., 2001); moreover, 
the phenotype from muscle-specific Glut4 deficient mice with glucose intolerance and 
diabetes can be rescued by selective overexpression of Glut4 in the adipose tissue of these 
mice (Carvalho et al., 2005; Huang and Czech, 2007).  
1.4.4 Skeletal muscle glycogen. 
As all cells, skeletal muscles need ATP to sustain muscle contraction, and ATP is not stored 
and becomes rapidly depleted in less than a second of intense exercise (Hultman and 
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Greenhaff, 1991), therefore other pathways leading to ATP production need to be activated. 
Glucose is an important molecule in muscle metabolism providing ATP through two different 
pathways, anaerobic and aerobic. After a meal under resting conditions an organism stores the 
ingested carbohydrates in the kidney (10 %), liver (25-35 %) and muscle (40 %) as glycogen. 
This stored glycogen acts as a stored energy source allowing the muscle to respond rapidly to 
any environmental signal when glucose is not available, making this tissue an important 
player for whole body metabolism (Argilés et al., 2016). Glycogen is a branched polymer of 
glucose presenting also small amounts of glucosamine. The branches can reach a size of 10-
44 nm and accumulate up to 55.000 glucose residues. Glycogen synthesis (glycogenesis) is 
coordinated by several enzymes, and a schematic diagram of this mechanism is shown in 
figure 1.9; firstly glucose enters the cells through the glucose transporter and becomes 
phosphorylated to glucose 6-phosphate by hexokinase isoenzymes; next, 
phosphoglucomutase-1 isomerize glucose 6-phosphate to produce glucose 1-phosphate; at this 
point, uridine 5ʹ-diphosphate (UDP)-glucose pyrophosphorylase catalyzes the formation of 
UDP-glucose from glucose 1-phosphate. The next step is the initial synthesis of glycogen by 
glycogenin, when this enzyme autoglycosylates and transports glucose from UDP-glucose to 
itself and forming a short linear chain of about 10–20 glucose moieties. The elongation of this 
small glycogen sequence is performed by glycogen synthase, which transfers a glycosyl 
moiety from UDP-glucose to the growing glycogen strand, providing the α-1,4-glycosidic 
linkages between glucose residues. The last part is completed by the glycogen branching 
enzyme, creating α-1,6 glycosidic bonds at regular intervals that allow the introduction of 
branch points in the glycogen particle (Adeva-Andany et al., 2016; Röder et al., 2016).  
Glycogen breakdown (glycogenolysis) principally takes place in the cytoplasm (and to a 
lesser extent in lysosomes). In the cytoplasm, glycogen phosphorylase releases glucose 1-
phosphate by untangling the α-1,4-glycosidic linkages, and secondly glycogen debranching 
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enzymes unfasten the branch points releasing free glucose; a scheme of this mechanism is 
shown in figure 1.9. In lysosomes, glycogen is degraded to glucose by the enzyme acid α-1,4-
glucosidase, hydrolyzing the 1,4-linked α-glucose polymers of the glycogen (Adeva-Andany 
et al., 2016).  
Glycogenolysis is tightly regulated by different hormones, insulin, epinephrine and glucagon. 
Epinephrine (also known as adrenaline) is released from the adrenal medulla during physical 
activity (muscle contraction) or its anticipation and induces glycogen breakdown in muscle 
and to a lesser extent in liver (Chasiotis, 1983). On the other hand, the polypeptide hormone 
glucagon is secreted by the α cells of the pancreas when the blood-sugar levels are low and, 
similarly to epinephrine also induces glycogen breakdown (Röder et al., 2016). When insulin 
is released to the blood stream, this hormone stimulates the translocation of Glut4 to the 
membrane, increasing the glucose uptake into the muscle and activating glycogen synthase, 
which promotes glycogen synthesis (Halse et al., 2005).  
The ECC machinery that allows muscle contraction largely depends on the energy obtained 
from ATP hydrolysis. The ATP stores in skeletal muscle are relatively small (~8 mmol/kg wet 
weight of muscle). Therefore the muscle relies on an ATP generation mechanism, which is 
based on complex store and energy sources such as glycogen (glucose) and triacylglycerols 
(Baker et al., 2010). Glucose oxidation occurs in the cytosol and continues under aerobic 
conditions in the mitochondria, producing 36 molecules of ATP for each molecule of oxidized 
glucose. On the other hand, the anaerobic cytoplasmic pathway only produces 2 molecules of 
ATP per molecule of glucose, but the rate at which ATP is produced is much faster than that 
occurring in mitochondria through the Kreb’s cycle. During low intensity aerobic exercise, 
carbohydrate oxidation accounts for 10–15% of total energy production (Holloszy et al., 
1998; Jensen and Richter 2012); the majority of this glucose originates from glucose uptake 
………. 
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Figure 1.9 Glycogen synthesis (glycogenesis) and Glycogen degradation (glycogenolysis) 
models.  Overview of the participial enzymes and the products involved in the glycogenesis 
and glycogenolysis, which take place in the cytoplasm (image modified from Adeva-Andany 
et al., 2016). 
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(plasma glucose) and only a small portion from glycogen stores. But during higher exercise 
intensity carbohydrate oxidation accounts for 70-80 % of total energy production and 
glycogen-breakdown becomes the predominant glucose source (Jensen and Richter 2012).  
For this reason high carbohydrate-diets are often used by elite athletes during training to 
increase muscle glycogen levels and increase the muscle’s fatigue resistance (Jensen and 
Richter 2012). Another important mechanism that produces ATP is the phosphagen system. 
During low intensity exercise the majority of ATP is generated by the conversion of 
phosphocreatine, protons (H
+
) and ADP to ATP and creatine. This reaction is catalyzed by 
creatine kinase and induces a slightly alkalinization of the muscle due to the H
+ 
consumption. 
On the other hand, during high intensity exercise the stores of phosphorcreatine decrease and 
the production of ATP by phosphagen system is reduced rapidly. For instance, after 10 
seconds of maximal exercise the phosphocreatine stores are depleted and almost all the ATP 
generation is comes from glycolysis. This means that the limiting step of phosphagen is the 
concentration of phosphocreatinine in the muscle (Baker et al., 2010).    
 
1.4 Mammalian target of rapamycin (mTOR).  
Mammalian target of rapamycin (mTOR) is a 289 kDa serine/threonine kinase that is the 
target of the immunosuppressant drug rapamycin. This kinase belongs  to  the  
phosphoinositide 3-kinase (PI3K)-related kinase family and is key component of the cell 
survival pathways that regulates cell growth and proliferation through monitoring the 
availability of nutrients, mitogenic signals, cellular energy and oxygen levels (Zarogoulidis et 
al., 2014). Disturbances of the mTOR signaling pathway have been associated with a variety 
of human diseases including diabetes, neurodegeneration and cancer. mTOR inhibitor 
(initially rapamycin and more recently rapamycin analogs) have been used to treat different 
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pathological cases as solid  tumors,  organ transplantation,     coronary     restenosis     and  
rheumatoid arthritis (Zarogoulidis et al., 2014; Kim et al., 2017). Molecular analysis of the 
anti-proliferative and cytostatic effect of rapamycin showed that this drug  blocks some but 
not all mTOR activities. More detailed investigations have revealed that mTOR acts in two 
functionally distinct multiprotein complexes (Sarbassov et al., 2004; Kim et al., 2012): mTOR 
complex 1 and 2 (mTORC1 and mTORC2, respectively). mTORC1 is characterized by the 
presence of a regulatory associated protein of mTOR called Raptor and Proline Rich AKT 
Substrate of 40 kDa (PRAS40), but also shares some proteins with mTORC2 such as mTOR, 
mammalian Lethal  with  Sec13 protein 8 (mLST8) and DEP-domain-containing mTOR-
interacting protein (Deptor). mTORC2 is recognized by the presence of Mammalian lethal 
with Sec13 protein 8 (mSin1) and Rapamycin insensitive companion of mTOR (Rictor) as 
show in the figure 1.10 (Laplante and Sabatini 2009).  
1.4.1 mTORC1  
The principal characteristic of mTORC1 is that it is rapamycin sensitive. Rapamycin binds  to  
FK506-binding  protein  of  12  kDa (FKBP12)   and   interacts   with   the   FKBP12 
rapamycin  binding  domain  (FRB)  of  mTOR, blocking it. Each component of the mTORC1 
macromolecular complex presents a different role in the activity of this complex, contributing 
to substrate specificity, subcellular localization and complex specific regulation; mTOR, is the 
central catalytic component; mLST8 works as scaffolding protein; DEPTOR is important for 
mTOR complex assembly and stability; Raptor is a scaffolding protein important in the 
assembly, stability, substrate specificity and regulation; and PRAS40, is a factor that blocks 
mTORC1 activity until growth factor receptor signaling relieves the inhibition, figure 1.10 
shows a scheme of the composition of the mTORC1 complex (Kim et al., 2017). mTORC1 is 
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affiliated with the endosomal and lysosomal membranes, where it interacts with its effectors 
4E-binding protein 1 and S6 kinase 1 (S6K1) (Laplante and Sabatini., 2009) 
mTORC1 signaling 
 The study of mTORC1 signaling has been a complicated task due to the multiples pathways 
related to this protein complex (see figure 1.10). The most common first step leading to its 
stimulation is the activation of PI3K in response to growth factor signaling. This leads to the 
increase in production of the second messenger phosphatidylinositol (3,4,5)-triphosphate 
(PIP3), directly activating Protein kinase B (AKT) by phosphorylating residue Thr308 and 
indirectly by PDK1 (Laplante and  Sabatini., 2009). 
AKT has two strong effects on mTORC1, the first is the phosphorylation of PRAS40 
(mTORC1 inhibitor) causing PRAS40 to dissociate from Raptor and allowing mTORC1 
activation; the second is indirect, by phosphorylating tuberous sclerosis complex 2 (TSC2), 
which brakes the TSC1-TSC2 complex, a negative regulator of the mTORC1 activator 
RHEB, (see figure 1.10). An additional similar pathway that induces the activation of 
mTORC1 involves Ras/Raf/MEK/ERK and RSK proteins. Where ERK and RSK proteins 
also phosphorylate TSC2 and PRAS40 proteins, breaking their inhibitory effects on 
mTORC1, which is an effect similar to that of AKT on mTORC1. On the other hand when the 
ATP/AMP ratio in the cell is low (meaning low cell energy), AMPK is activated and 
indirectly inhibits mTORC1 activity, by promoting TSC1/2 complex formation, as  show in 
Figure 1.10 (Inoki et al., 2003; Kim et al. 2017). Downstream changes accompanying 
mTORC1activation include the phosphorylation of different substrates, such as eukaryotic 
translation initiation factor 4E-binding protein 1 (4EBP1) and ribosomal protein S6 kinase 1 
(S6K1), which increases cell size and proliferation (Dowling et al., 2010). 
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Figure 1.10 Composition and signaling pathways of mTORC1 and mTORC2. A) 
Schematic representation of mTOR1 and mTORC1 complexes with their protein components. 
B) Overview of the mTORC1 and mTORC2 signaling pathway, showing the most important 
proteins and molecules involved in the activation and inhibition of these two complexes 
(image modified from Kim et al., 2017). 
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translation initiation factor 4E-binding protein 1 (4EBP1) and ribosomal protein S6 kinase 1 
(S6K1), which increases cell size and proliferation (Dowling et al., 2010). 
1.4.2 mTORC2  
One of the principal characteristics of mTORC2 is its insensitivity to the effect of 
rapamycin..In mTORC1 FKBP12 inhibits mTOR in the FKBP12-rapamycin complex binding 
domain, but in mTORC2 FKBP12 cannot interact physically most probabll because Rictor 
blocks the FKBP12-rapamycin complex binding site in mTOR (Jacinto et al., 2004; Sarbassov 
et al., 2004). Aside the three proteins (mTOR, mLST8, Deptor) that mTORC2 shares with 
mTORC1, mTORC2 also contains Rictor, which is important in the assembly, stability, 
substrate identification and subcellular localization of this complex to the appropriate sites of 
action. Furthermore, mSin1, is also part of the mTORC2 complex and is necessary for the 
subcellular localization of mTORC2 to the plasma membrane as shown in figure 1.10 (Kim et 
al., 2017). mTORC2 was found to be associated with the plasma membrane and ribosomal 
membranes, where it interacts with its key substrates, the AGC kinases including AKT1-3, 
serum glucose kinase (SGK) isoforms and protein kinase C (PKC) family members 
(Sarbassov et al. 2005; Zinzalla et al. 2014). 
mTORC2 signaling 
Even though cofactors such as insulin and IGF-1 are able to activate mTORC1 and mTORC2, 
the difference in protein composition of the two complexes can induce completely different 
responses but studies aimed at elucidating the biological role of mTORC2 have been 
complicated by the fact that there are no specific pharmacological inhibitors for mTORC2. 
Because of this, genetically modified animals have been created, such as muscle-specific 
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rictor knockout mice, to determine the role of mTORC2 in skeletal muscle function 
(Bentzinger et al 2008; Sarbassov et al. 2004). 
mTORC2 is activated by growth factor and ribosome association (Sarbassov et al. 2004; 
Zinzalla et al., 2011). The second messenger PIP3, which is produced by PI3K, recruits and 
activates mTORC2 (figure 1.10 presents a schematic representation of mTORC2 pathway). At 
this point mTORC2 is located close to the cell membrane in close proximity to its three 
substrates, AKT, SGK, and PKC. mTORC2 is the only complex that phosphorylates AKT at 
serine 473 under physiological conditions (Vadlakonda et al. 2013) and recent studies show 
that a positive feedback loop between mTORC2 and AKT ser473 exist. AKT phosphorylates 
mSin1 at T86 enhancing mTORC2 kinase activity and mTORC2 phosphorylates AKT ser473, 
catalyzing the full activation of AKT. The physiological consequences of AKT activation are 
very broad, including effects on metabolism, cell growth, proliferation, cell survival and 
motility (Yang et al 2015; Kim et al., 2017). SGK activation by mTORC2 induces the 
activation of NDRG1 and FoxO family transcription factors. These two factors are able to 
promote cell survival signals in response of oxygen or nutrient deprivation (Bakker et al 
2007). On the other hand, the effect of PKC activation by mTORC2 is still not very clear. It is 
known that PKC is involved in different cellular functions as proliferation, apoptosis, 
differentiation, motility, and inflammation, but the responses induced by activation or 
overexpression of PKC highly depending on the types of cell and and physiological 
conditions (Nakashima et al., 2002; Kim et al., 2017).  
1.5 Retinoic acid and Vitamin A 
For the production of retinoic acid, vertebrates including humans, need to consume vitamin A 
(retinol) with the diet (it is present in plant carotenoids and to a lesser extent in meat), since 
they are unable to synthesize this vitamin. Deficiency of this vitamin in newborns causes 
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neonatal growth retardation and different congenital malformation (vitamin A deficiency 
syndrome), and importantly retinol and its derivatives (retinoids) play an important role in 
spermatogenesis, fertilization, pregnancy maintenance, morphogenesis, organogenesis and 
general fetal and perinatal growth. In adults, retinol and retinoids regulate a wide spectrum of 
physiological processes involved in maintaining the proper functions of skin, lung, bone 
marrow, liver, and neuronal system and are also associated with regulation of reproduction, 
immunity, vision and metabolism (Zhang et al., 2015). atRA has been also shown to work as a 
potent therapeutic compound in multiples diseases due to its anti-proliferative, anti-oxidative, 
pro-apoptotic, and differentiation-inducing effects (Persaud et al., 2016). For instance, 
pharmacological administration of vitamin A (or retinoids) has shown important results in the 
treatment of acne and myelocytic leukemia. Acne is a consequence of abnormalities in the 
proliferation, adhesion and differentiation of keratinocytes, which no longer separate from 
each other, and obstruct the sebaceous duct located in the infrainfundibulum. Retinoids (all-
trans-retinoic acid, atRA and 13-cis-retinoic acid) act against acne inducing the differentiation 
and proliferation of keratinocytes. Furthermore these vitamin A derivatives are able to 
regulate the activity of the adhesion molecules that ensure the normal cohesion of 
keratinocytes (Chivot, 2005). On the other hand, retinoids (especially atRA) have been very 
useful to induce differentiation of blast cells in patients with myelocytic leukemia. Using 
differentiation markers (cell surface myeloid antigens CD11b, CD15, CD14, and CD33) to 
monitor blast differentiation Sartorelly`s group (Rise et al., 2004) observed that atRA is able 
to produce changes in at least one surface antigen differentiation marker in 89% of patient 
blasts. In presence of lithium chloride atRA was able to induce the differentiation of leukemic 
blasts in up to 94% of patients. These myelocytic leukemia progenitors cells exposed to atRA 
in vitro or during clinical treatment continued their differentiation program into neutrophils 
which eventually resulted in their senesce (Rise et al., 2004; Su et al., 2015). 
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1.5.1 Vitamin A signaling 
Once ingested, vitamin A is taken up by the intestinal epithelial cells in the small intestine and 
is stored in the liver or sent through the blood circulation to different tissues. The retinols bind 
to retinol-binding proteins (RBP) and such complexes interact with the RBP receptor 
(STRA6), which is specifically expressed on target cells. Once inside the cell, the retinol can 
be used to produce retinyl esters such as palmitate or be hydrolyzed by alcohol 
dehydrogenases (ADHs) to  
 
Figure 1.11. Retinol (vitamin A) pathway. Retinol enters the cell through STRA6 and is 
converted to RA (atRA) by different enzymes, to be subsequently transported into the nucleus 
and interact with RAR, inducing the transcription of several target genes (Carretero et al 
2013).  
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retinaldehyde (retinal) in a reversible way, as shown in figure 1.11. The formation of retinoic 
acid (RA) represents the irreversible step, taking place when retinaldehyde dehydrogenases 
(RALDHs) hydrolyzes retinal to RA. Depending on the cell’s energy levels, the RA can bind 
to the RA-binding protein 1 (CRBPI) and be targeted for degradation or it could bind to 
CRABPII and be transported into the nucleus where it interact with the Retinoic Acid 
Receptors (RAR), a family of ligand-dependent regulators of transcription. There are three 
separate RAR genes encoding nuclear receptor, RARα, RARβ and RARγ, which will be 
discussed in more detail in section 1.6.1. RARs can heterodimerize with retinoic X receptors 
(RXR), inducing the transcription of different RA target genes connected to cell growth, 
differentiation, development, and tissue homeostasis (Huang et al. 2014; Larange and 
Cheroutre, 2016).   
The effect of RA on organisms is still a dynamic topic, with classical experiments showing 
that in some cells atRA interacts with the RAR and induces the expression of genes involved 
in apoptosis, cell growth inhibition, cell cycle arrest and anti-carcinogenic activities in 
different tissues and cancer cells (Altucci et al., 2001; Donato and Noy, 2005; Schug et al., 
2007). But contradictorily results have been obtained by other groups showing that atRA can 
promote cell proliferation..atRA is critical for neuronal survival, induces skin tumor formation 
and stimulates dermal repair by causing the expression of target genes related to mitogenisis 
and antiapoptotic responses (Verma et al., 1982; Jacobs et al., 2006; Schug  et al, 2007). 
These opposite effects have been explained by the participation of two different proteins, 
cellular RA-binding protein II (CRABP-II) and fatty acid-binding protein 5 (FABP5). 
Depending on the CRABP-II/FABP5 ratio, RA will bind to CRBP-II (when the ratio is high) 
or to FABP5 (when the ratio is low). Once atRA binds to CRBP-II this is mobilized to the 
nucleus where it interacts with the RAR (as explained in the section above); on the other hand 
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when RA binds to FABP5, it is mobilized to the nucleus, and associates with peroxisome 
proliferation-activated receptor β/δ (PPARβ/δ) (Schug  et al, 2007; Berry, and Noy, 2009).  
1.6 Genomic effects of atRA. RAR and RXR. 
Retinoic Acid Receptors and Retinoic X Receptors, are ligand-transcription factors that can 
function as heterodimers, regulating gene networks involved with different physiological 
functions, including cell proliferation, differentiation, senescence and apoptosis. RAR-RXR is 
an important heterodimer that control multiple physiological phenomena through the 
modulation of transcriptionof different gene; additionally each nuclear receptor (RAR and 
RXR) can respond in a specific manner to specific physiological conditions. For instance, 
RXR is able to form heterodimers with a large number of nuclear receptor family members 
(PPARs, LXRs, PXR, VDR, TR), activating multiple cellular pathways in response to RXR-
selective ligands (Le Maire et al,. 2012). 
1.6.1 Retinoic acid receptor. 
RA and its isomer 9-cis RA bind to RARs, regulating the expression of over 500 genes. In   
the absence of ligands RAR actively repress transcription by establishing a co-repressor 
(CoR) complex with HDACs, and other repressive factors (Le Maire et al., 2012). RAR is 
present in 3 different isoforms, RARα, RARβ, and RARγ and each of these receptors is 
encoded by genes located on different chromosomes that use different promoters giving rise 
to alternatively spliced variants following a spatial and temporal specific pattern during 
embryonic development and adulthood (Dollé et al., 1989, Theodosiou et al., 2010). 
RARα represent a ubiquitously expressed receptor and RARα null mice show decreased 
viability, growth deficiency, male infertility and congenital malformations that could be 
reversed by RA treatment (Mark et al., 2009; Theodosiou et al., 2010). During mouse 
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embryogenesis RARβ is specifically distributed in tracheobronchi, lungs, the genital tract and 
intestinal epithelial cells (Dollé et al., 1989; Desaia et al., 2006) and during adulthood in the 
brain (Krezel et al 1999). RARβ null mice present locomotor defects and selective loss of 
striosomal compartmentalization in the rostral striatum. The RARγ is also tissue specific and 
is found in skeletal muscle. RARγ null mice present growth deficiency, early lethality and 
male sterility (similar effects observed in vitamin A deficient mice), and the phenotype could 
be rescued with RA treatment (Lohnes et al., 1993). 
Metabolic related effects of RAR have been shown when adult mice overexpressing a 
dominant-negative RARα mutant that induces a hypomorphic RAR in β cells caused a 
decrease of β cell mass and glucose-stimulated insulin secretion. These results indicate that 
RARs is also involved in maintaining the function and mass of pancreatic β cells (Brun et al., 
2015). RAR have also been connected with the regulation of RA-inhibited adipocyte 
differentiation by controlling adipogenesis-related gene expression. RAR can also induce the 
activation of uncoupling protein 1 (Ucp1) and hormone lipase (Hsl), genes involved in energy 
expenditure (Berry and Noy. 2009) and such as Gck and insulin-like growth factor-binding 
protein 1 (Igfbp1) (Scribner et al 2007).  
1.6.2 Retinoic X receptor 
RXR are unable to interact directly with RA, but as mentioned above, can complex with RAR 
and also have a high affinity for 9-cis RA. RXR produce homodimers and heterodimers with 
RXR and other nuclear receptors (NR), respectively and their transcriptional activation 
depends highly on the nature of their partner. In the case of RAR/RXR heterodimers the 
ligand-bound RXR is not active until RAR interact with its ligand.  
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The RXR, RXRβ and RXRγ are three different isoform of RXR. They are encoded by 
different genes and are also expressed in specific patterns during development. RXRα and 
RXRβ are amply distributed for example in the eye, cardiac muscle, liver, epidermis, prostate 
gland, etc..  While RXRγ is highly tissue specific, mainly expressed in skeletal muscle and to 
a lower extent in sensory epithelia of visual and auditory systems and in the central nervous 
system.  RXRα/RAR, and the different combinations of RXRα/RARα, RXRα/RARβ, and 
RXRα/RARγ heterodimers are involved in developmental processes. Studies with mutant 
RXRs genes indicate a critical role of these heterodimers since mutant mice embryos die in 
mid-gestation due to congenital heart, metabolic and behavioral defects (Krezel et al., 1996). 
Tissue specific conditional knockout mice show that RXRα plays an essential role in multiple 
pathways including glutathione homeostasis and detoxification of xenobiotics, regenerative 
capacity of hepatocytes, proliferation and differentiation of epidermal keratinocytes, and 
development of prostatic intraepithelial neoplasia (Li et al 2000; Wu et al., 2004; Chan und 
Wells, 2009). Fifty percent of the RXR β knockout mice (RXRβ-/-) mice die before or at 
birth. The other 50 % that survive showed physiological deficiencies including sterility of 
male mice due to oligo-astheno-teratozoospermia. The sertoli cells of these surviving mice 
presented a progressive accumulation of lipids (triglycerides) indicainge the interaction of 
RXRβ with the peroxisomal proliferator-activated receptor signaling pathway (Kastner et al 
1996; Krezel et al., 1996). Lastly, RXRϒ knockout mice were indistinguishable from their 
wild-type littermates with respect to growth, fertility, viability and behavior (Krezel et al., 
1996).  
1.6.3 Non genomic effects of atRA. 
The genomic effect of steroid hormones occurs after a time lag of several hours, altering 
target gene expression for an extended period of time. On the other hand, non-genomic steroid 
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actions occur much faster, with a duration of minutes to seconds, and affecting multiple 
signaling pathways (Persaud et al., 2016).  
The role of atRA in the regulation of gene transcription is well known but in recent years a 
different kind of RA effect has been observed. RA has been associated with extranuclear-
related and non-transcriptional dependent activities, that transiently activate several kinase 
cascades (Tanoury et al 2013). In different cell types such as fibroblast, mammary breast and 
leukemia cells, atRA activates the p38 mitogen-activated kinase (p38MAP). In myeloid 
leukemia and breast cancer cell lines atRA is able to activate protein kinase C δ (Zhang et al., 
2015) and in other cells types such as neuronal, Sertoli and embryonic stem cells, RA triggers 
the activation of p42/p44 extracellular signal-regulated kinases (Erk) and finally activation of 
MAPKs proteins (Cheung  et al., 2009; Lösel and Wehling, 2003; Zhang et al., 2015).  
Non genomic effect mechanism.  
Even if there is strong evidence for the non-genomic effects of atRA on different cell types, 
the intracellular signaling pathway of this molecule is poorly understood. Different 
experiments exposed two main pathways, through RARs or cellular retinoic acid binding 
protein 1 (CRABP1) (Tanoury et al., 2013; Persaud et al., 2016). The atRA non-genomic 
effect through RARs activation acts in different ways depending of the cell type and RARs 
involved (see figure 1.12). Firstly, RA activates Gαq protein in fibroblasts, embryo carcinoma 
cells, mammary breast tumor cells, and leukemia cells, inducing the activation of downstream 
proteins such as GTPases, p38 mitogen-activated protein kinase (p38MAPK) and Mitogen- 
and stress-activated kinase 1 (MSK1), as shown in figure 1.12. The activation of MSK1 
triggers the phosphorylation of CREB and Histone H3, which regulate a specific subset of 
immediate early genes (Bruck et al., 2009; Reyskens and Arthur 2016). On the other hand in 
Sertoli cells and embryonic stem cells treated with atRA activation of p42/p44 extracellular 
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signal-regulated kinases (Erks) has been observed. Possible upstream activators, of these 
signaling pathways include the Src-family protein kinases/RARγ or phosphoinositide 3-kinase 
(PI3K)/protein kinase B (PKB/AKT) (Figure 1.12) (Masia et al., 2007; Tanoury et al., 2013). 
Additionally experimental results also demonstrate that retinol directly activates Signal 
transducer and activator of transcription 5 (STAT5) by association with Retinol-binding 
protein (RBP) through the activation of Janus kinases (JAK), see figure 1.12 (Berry et al., 
2011; Tanoury et al., 2013). 
 
Figure 1.12. Extranuclear and non-transcriptional effects of RA and retinol. RAR and 
retinol activating transitorily RARα, RARϒ and Retinol-RBP, inducing the activation of 
MSK1, Rsk and STAT5 downstream proteins of these signaling pathways (image from 
Tanoury et al., 2013). 
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Another recently proposed mechanism in which atRA acts through a non-genomic effect is 
based on the activation of cellular retinoic acid binding protein 1 (CRABP1), in an RAR-
independent manner (Persaud et al., 2016). This pathway implicates the activation of the 
extracellular signal regulated kinase 1/2 (ERK1/2) in embryonic stem cells (ESC), in a 
manner similar to non-genomic RAR.  Activation of ERK1/2, triggers the activation of 
protein phosphatase 2A (PP2A) regulating cell cycle progression and induction of apoptosis. 
This (CRABP1) pathway represents an important target since it is independent of RAR 
activation. Treatment of cancer patients with atRA has resulted in negative toxici side effect, 
which are mainly attributed to retinoids’ canonical, genomic actions through binding to 
RARs. Additional negative effects of this pharmacological treatment of cancer patients, is that 
at therapeutic doses atRA loses efficacy due to the development of RA resistance (RAR 
related). For these reasons it is important to find new drugs that specifically bind to Crabp1 to 
elicit activity mimicking atRA’s non-genomic (RAR-independent) activity (Persaud et al., 
2016). 
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ABSTRACT: 
SRP-35 is a short-chain dehydrogenase/reductase belonging to the DHRS7C dehydrogenase/ 
reductase family 7. Here we show that its over-expression in mouse skeletal muscles induces 
enhanced muscle performance in vivo, which is not related to alterations in excitation-
contraction coupling but rather linked to enhanced glucose metabolism. Over-expression  of 
SRP-35 causes increased phosphorylation of AKTS473, triggering plasmalemmal targeting of 
GLUT4 and higher glucose uptake into muscles. SRP-35 signaling involves RARα and RAR 
(non-genomic effect), PI3K and mTORC2. We also demonstrate that all-trans retinoic acid, a 
downstream product of the enzymatic activity of SRP-35, mimics the effect of SRP-35 in 
skeletal muscle, inducing a synergistic effect with insulin on AKTs473 phosphorylation. These 
results indicate that SRP-35 affects skeletal muscle metabolism and may represent an 
important target for the treatment of metabolic diseases. 
 
Key Words: SRP-35, glucose, metabolism, retinoic acid, mTORC2, AKT phosphorylation, 
skeletal muscle.  
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INTRODUCTION 
Skeletal muscle is the largest body organ comprising approximately 40% of total body 
weight under normal conditions, it is important not only important for movement and posture 
but also for metabolism and thermogenesis (1, 2). Furthermore, skeletal muscle adapts to 
different environmental conditions and load requirements by modifying its fiber type 
composition and glycolytic or oxidative characteristics (3, 4). Muscle fiber type composition 
is determined mainly by the expression of specific myosin heavy chain isoforms: MyHC I in 
slow fibres, MyHC type IIa in fast oxidative fibres and MyHC IIx/b in fast glycolytic fibres 
(4, 5). The differences in contractile properties between slow and fast fibers also depends on 
the higher density of sarco/endoplasmic reticulum Ca
2+
-ATPase (SERCA), expression of 
Ca
2+
- binding proteins such as parvalbumin, calsequestrin 1 and calsequestrin 2, and a higher 
mitochondrial content in slow type I fibers compared to fast type II fibers (4, 6, 7).  
Skeletal muscle is responsible for 70-75 % of the insulin stimulated glucose uptake 
(8); part of the energy obtained from glucose is used to fuel muscles and the remaining is 
stored as glycogen (9). Two glucose transporters are expressed in skeletal muscle: GLUT4 
and GLUT1 which are insulin-sensitive and insulin-insensitive, respectively (10-12). Insulin 
receptor stimulation activates a number of downstream signaling proteins including 
phosphoinositide 3-kinase (PI3K) and protein kinase B (PKB or AKT) which induce GLUT4 
translocation to the plasma membrane where it facilitates blood glucose clearance and glucose 
uptake into muscles (9, 13). 
In the past years our laboratory has discovered novel proteins of the skeletal muscle 
sarcoplasmic reticulum (SR) (14). One such protein we identified at the molecular level is 
SRP-35, a 35 kDa membrane bound protein enriched in sarcotubular membranes. The NH2-
terminus of SRP35 encompasses a short hydrophobic sequence associated to SR membranes, 
whereas its C-terminal domain faces the myoplasm. Sequence comparison and functional in 
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vitro experiments established that SRP-35 is a short-chain dehydrogenase/ reductase 
belonging to the DHRS7C [dehydrogenase/reductase (short-chain dehydrogenase/reductase 
family) member 7C] subfamily (15, 16), using retinol (Vit. A) as its substrate and leading to 
the formation of all-trans-retinaldehyde (17). The latter is the substrate for an irreversible 
oxidative reaction generating all- trans retinoic acid (atRA). Retinoic acid (RA) acts as a 
ligand for nuclear receptors of the RAR and RXR family, mediating the transcriptional effect 
of RA on genes involved in tissue development and cell differentiation (18). Recent studies 
have also revealed that atRA influences cell metabolism (19, 20), by modulating, the (i) 
phosphorylation state of AMPK and AKT (21) and (ii) rate of glucose uptake by L6 myotubes 
(22). 
Because of the important metabolic role of RA, we generated a transgenic mouse line 
overexpressing SRP-35 in skeletal muscle. Our results show that these transgenic mice 
(SRP35TG) exhibit enhanced running capacity, enhanced glucose uptake leading to larger 
glycogen stores. Furthermore, the presence of the transgene induces a stronger activation of 
PI3K and of mammalian target of rapamycin complex 2 (mTORC2) signaling pathways, 
triggering the phosphorylation of AKTS473 which account for GLUT4 translocation onto the 
plasma membrane. The metabolic changes observed in SRP35TG mice could be mimicked by 
treating skeletal muscles of wild type mice with atRA.  
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RESULTS 
Impact of SRP-35 over-expression on the expression of SR ECC proteins and on muscle 
function 
We generated TG mice encoding mouse SRP-35 under the skeletal muscle specific creatine 
kinase promoter (Supplementary Figure 1A). The presence of the transgene was confirmed by 
polymerase chain reaction (PCR) (Supplementary Figure 1B), Coomassie Blue staining on a 
total SR extract of skeletal muscle from WT and SRP35TG mice (Supplementary Fig.1C 
asterisk) and Western blotting. We obtained three mouse lines expressing the TG to different 
extents: line 4, 5 and 6 over-expressing SRP-35 by 28%, 61 % and 23%, respectively 
(Supplementary Fig. 1D). In this study, we performed most of the experiments on muscles 
from line 5 and their respective wild-type (WT) littermates but similar results were obtained 
on the other TG lines. We first investigated in vivo and in vitro muscle function using the 
voluntary running wheel and electrically stimulated force generation, respectively. Figure 1 
shows that after 21 days young (7 months, Fig.1A left panel) and old (14 months, Fig. 1A 
right panel) SRP35TG male mice (closed circles) ran approximately 50 Km more (n=16 
p<0.001, Mann Whitney test) compared to their age matched WT littermates (Fig. 1A, open 
circles). The higher running capacity of the SRP35TG mice between day 15 and day 20 is also 
paralleled by a remarkable increase in the number of 10 s high speed events (>2.5 km/hr) 
occurring during the dark phase (Fig. 1B). The enhanced running capacity is not linked to 
changes in fiber type composition since we found an equal distribution of MyHC I and MyHC 
II positive fibers in extensor digitorum longus (EDL) and soleus muscles in WT and 
SRP35TG mice (Fig. 1C). However, over-expression of SRP-35 caused a small (10%) but 
significant (p<0.05 Student's t test) increase of the minimal Feret’s diameter of MyHC type I 
and MyHC type II fibers (Fig. 1D and Fig1 E) in soleus. The mechanical properties of WT 
and SRP35TG mice are similar (Fig. 1F and Supplementary Table 1) indicating that the 
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enhanced running is not due to a gain of function of the excitation-contraction coupling 
(ECC) mechanism. This conclusion is also consistent with the absence of changes in the 
content of RyR1, Cav1.1 and calsequestrin, the main proteins constituting the ECC 
macromolecular complex (Fig. 1G). On the other hand, SRP-35 over-expression was 
accompanied by a significant reduction of the ER(SR) calcium binding protein calreticulin  
(n=6, p<0.01, Student’s t test) and of the β1a subunit of the dihydropyridine receptor (n=6 
p<0.01, Student’s t test). SRP35TG muscles also display a 40% increase of glycogen 
phosphorylase content (GP; Fig. 1G; n=6 p<0.01, Student’s t test), a key enzyme involved in 
glucose metabolism activation during muscle contraction (23). Because of this increase of 
glycogen phosphorylase we hypothesized that the enhanced running capacity was the result of 
an effect on glucose metabolism.  
SRP35TG mice show enhanced glucose metabolism.  
In vivo glucose clearance was performed by the intraperitoneal glucose tolerance test (ipGTT) 
in young and old (7 and 16 months old, respectively) mice. Both age groups of SRP35TG 
mice showed a two-fold reduction in serum glucose levels 60 min after the glucose challenge 
compared to their WT littermates (Fig. 2A; n=8 p<0.05, Student’s t test). Additionally, there 
was a significant difference in glucose clearing kinetics between young and old WT mice at 
90 and 120 min. Interestingly in SRP35TG mice the glucose clearance curves of young and 
old mice were similar, with no delay in clearance, suggesting a protective effect of SRP-35 
over-expression in age-related glucose uptake processes (23). The enhanced glucose clearance 
was not related to altered levels of insulin release, as blood insulin levels were similar in WT 
and SRP35TG mice (Fig. 2B). 
Skeletal muscles express two main types of glucose transporters, GLUT1 which is insulin 
insensitive and GLUT4 which is exocytosed onto the plasma membrane in response to 
insulin. GLUT1 expression levels in total muscle homogenates and in the R1 fraction 
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enriched in transverse tubules and plasma membrane (25), was similar in WT and SRP35TG 
mice (Supplementary Fig. 2A and 2B). On the other hand GLUT4 expression in SRP35TG 
mice was approximately 50% higher  (n=7 p<0.01, Student's t test) compared to WT 
littermates (Fig. 2C). The total amount of GLUT4 in the total muscle homogenates from both 
EDL and soleus was unchanged (Fig. 2D), indicating that SRP35TG mice constitutively 
activate or activate more efficiently the signal(s) responsible for GLUT4 translocation onto 
the plasma membrane and that the increased membrane expression of GLUT4 is not caused 
by enhanced synthesis of this transporter. 
The increased running capacity of SRP35TG mice may thus be related to the enhanced 
capacity of their skeletal muscles to remove circulating glucose and store it. We verified this 
directly (i) by monitoring the capacity of isolated muscles to take up glucose and (ii) by 
monitoring muscle glycogen stores. EDL and soleus muscles were assessed for their capacity 
to take up 2-deoxy-D-glucose-[
3
H]) by three different protocols, namely (i) no stimulation, 
(ii) after challenge with insulin (100 nM for 10 min), and (iii) by  a train of action potentials 
delivered  at 80 Hz for 5 min (Fig 3A). Under basal conditions, 2-DG-[
3
H] uptake in muscles 
from SRP35TG (7 months old) male mice was significantly increased compared to WT 
littermates (Fig. 3A n=8; p<0.05 Student’s t test). This difference in glucose uptake was 
further increased either by insulin treatment or electrical stimulation. Insulin promoted more 
glucose uptake by EDL and soleus muscles of SRP35TG mice (Fig.3A filled bars n=6; p<0.05 
Student’s t test) compared to WT littermates (Fig. 3A, empty bars). Muscles from SRP3TG 
mice accumulated more 2DG-[
3
H] compared to those from WT littermates also after electrical 
field stimulation (Fig. 3A n=6; p<0.05 unpaired t test). Altogether our data demonstrates that 
both fast and slow muscles isolated from SRP35TG mice show significant higher glucose 
uptake compared to WT littermates, and that the highest increase in glucose uptake was 
observed after insulin stimulation. Glucose taken up by muscles is stored as glycogen, a 
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glucose polymer acting as a readily available energy store for muscle activity. Thus the higher 
glucose uptake by SRP35TG muscles should result in larger glycogen stores and this was 
directly verified by assessing glycogen content by an enzyme coupled assay. Figure 3 B 
shows that the glycogen content in muscles from 7 months old SRP35TG male mice was 
around 30 % higher compared to that in WT littermates (n= 6; p<0.05 Student’s t test). Since 
muscle glycogen content is an important factor determining the respiratory exchange rate 
(RER), we also assessed basic metabolism using a CLAMS apparatus. Fig. 3C shows 
cumulative RER of WT (empty circles) and SRP35TG (filled circles) littermates. Each data 
point represents the average of RER from 7 months old male mice and shows a high degree of 
variability. There were no significant differences in the RER during the dark phase. However, 
10 out 23 RER data points of the light phase acquired on the last day of measurements were 
significantly increased in SRP35TG mice compared to WT (n= 8; p<0.05 Student’s t test). 
These events likely result from an increase of voluntary motor activity because we observed a 
parallel significant increase of the infrared beam breaks data points (Fig. 3D).  
Overexpression of SRP-35 affects AKT and AMPK phosphorylation  
GLUT4 membrane translocation and glucose uptake in skeletal muscle result from the 
activation of two major pathways, namely AKT and AMP-activated protein kinase (AMPK). 
AKT activation is linked to the stimulation of the insulin receptor, while AMPK activation 
may occur via multiple mechanisms, including muscle contraction (26). To assess the 
involvement of these signaling pathways we performed quantitative western blot analysis and 
determined the degree of phosphorylation of AKT (Ser473 and Thr308) and AMPK (Thr172) 
in total muscle homogenates. Our results show that in muscles from SRP35TG and WT (7 
months old) male mice the absolute content of AKT and AMPK in EDL and soleus at rest, 
after electrical stimulation or after the addition of insulin are similar (Fig. 4). Under resting 
conditions in soleus muscles the level of phosphorylation of AMPKThr172 was similar in 
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SRP35TG and WT littermates (Fig. 4A and Fig. 4B), whereas EDLs from SRP35TG show a 
significant increase (n=6; p<0.05, Student’s t test) of AMPKT172 phosphorylation compared to 
WT littermates (Fig. 4A and 4B). Upon delivery of a repetitive train of action potentials the 
phosphorylation level of AMPKT172 in EDL from SRP35TG mice was further increased from 
resting levels by 49.3% (Fig. 4C and Fig. 4D, p<0.05 Student’s t test), whereas in soleus the 
increase was not statistically significant (Fig. 4C and Fig. 4D). As to the phosphorylation 
level of AKT, we found different effects concerning Thr 308 and Ser 473, namely 
overexpression of SRP-35 only increases the phosphorylation of Ser 473 in both EDL and 
soleus (results for AKTt308 are not shown). Under resting conditions we observed an increase 
of the AKTS473 phosphorylation level in EDL and in soleus, respectively (286.1±132% and 
251±137%, mean ±S.D., n=7, p<0.05, Student’s t test; Fig. 4A and Fig. 4B). Insulin caused a 
further increase of the resting phosphorylation level of AKTS473 in EDL and soleus muscles by 
58 and 40%, respectively (n=7, p<0.05, Student’s t test Fig. 4E and Fig. 4F).  
atRA causes AKTS473 phosphorylation  
Although the exact mechanism by which SRP-35 affects AKT phosphorylation is not know, it 
might be due to the formation of RA resulting from the oxidation of all-trans-retinaldehyde, 
the precursor of RA generated by the up-regulation of the SRP-35 dehydrogenase activity (17) 
in muscles of SRP35TG mice. We tested this by assessing whether the phosphorylation of 
AKTS473 could be mimicked by treatment of muscles from WT mice with pharmacological 
concentrations of atRA (27). Treatment of intact EDL and soleus muscles for 30 and 60 min 
with 10 M atRA alone did not cause significant changes in the total amount of AKT and 
AMPK protein content (see Supplementary Fig. 2C) and had no effect on the phosphorylation 
status of AKTS473, AKTT308, and AMPKT172 (Fig. 5A and Fig. 5C). However, atRA may 
synergize with activators of the AKT and AMPK signaling pathways (28). Indeed incubation 
of intact EDL and soleus muscles with atRA in the presence of insulin significantly stimulates 
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the phosphorylation of AKTS473 by 166.6±24% and 173.6±44%, respectively (mean±S.D., 
n=6, p<0.05, Student’s t test). This increase occurred after 30 min and subsequently declined 
to control values by 60 min. The effect of atRA in the presence of insulin was specific for 
AKTS473 since we did not observed an increase in the phosphorylation of either AKTT308 or 
AMPKT172 (Fig. 5B and Fig. 5D). The fast time course of atRA-induced AKTS473 is consistent 
with a non-genomic action and this was further investigated by testing the effect of Retinoic 
acid Receptor (RaR) RAR, RAR and RAR inhibitors on AKTS473 phosphorylation. Fig. 
5E and Fig. 5F show that phosphorylation of AKTS473 induced by atRA in the presence of 
insulin was abolished by RAR and RARinhibitors and was insensitive to the 
RARinhibitor  
atRA stimulation of  AKT phosphorylation is mediated by mTOR complex 2 
 The higher extent of phosphorylation of AKTS473 in SRP35TG mice and the in vitro 
experiments with atRA may result from the activation of the Rictor/mTORC2 complex (29-
31). In order to verify this we performed control experiments on muscles isolated from muscle 
specific Rictor knock-out (RImKO) mice (32), a mouse model exhibiting down-regulation of 
the mTORC2. EDL and soleus muscles from (3 months old) male RImKO mice were treated 
with 100 nM insulin in the presence or absence of 10 M atRA. Under these conditions the 
RImKO mice failed to show significant changes in AKTS473 phosphorylation (Fig.6 A and 
Fig. 6B). This effect is specific since under identical experimental conditions phosphorylation 
of AKTS473 occurred in EDL and soleus muscles from WT littermates.  
PIP3 content in total muscle homogenates from WT and SRP35TG mice. 
The data obtained with RImKO mice demonstrate that atRA synergizes with physiological 
activators in triggering the enzymatic activity of mTORC2. PIP3, a product of the PI3K 
signaling pathway, is a physiological activator of the kinase activity of mTORC2 (33, 34). We 
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next measured PIP3 content in EDL and soleus muscles from SRP35TG and WT mice. Fig. 
6C and 6D shows that both EDL soleus muscles from (4 months old) male SRP35TG mice 
have a significant increase of PIP3 content (p<0.05, Mann-Whitney test). The intracellular 
level of atRA is influenced by the content of Vitamin A in the diet and a reduction of Vitamin 
A from 14 to 4 IU/g in the mouse chow was reported to induce a decrease in atRA content in 
various mouse tissues (35). We assume that at any given intracellular retinol concentration the 
muscle fibres over-expressing SRP-35 would generate greater amounts of all-trans-
retinaldehyde the precursor of the irreversible oxidation reaction leading to atRA formation. 
Thus one would expect that if mice were fed a low Vitamin A diet, the SRP35TG mice would 
generate more atRA compared to WT littermates and that the higher atRA levels would be 
associated with enhanced PI3K activity. We found that in (4 months old) male mice that had 
been fed for two generations with a low vitamin A (4 IU/g) diet, the PIP3 content in EDL and 
soleus muscles from WT mice under resting conditions was below the detection limit of the 
method (EDL) or barely detectable (soleus), whereas in EDL muscles from SRP35TG 
littermates the level is approximately 10% of that measured in EDL muscles of mice fed a 
standard chow (Fig. 6C lower panel) and in soleus muscles the levels is approximately 70% of 
that measured in soleus muscles of mice fed a standard chow diet.  The higher PI3K activity 
in muscles from SRP35TG kept on a low vitamin A diet should enhance mTORC2/AKT 
signaling which in turn may lead to higher glucose uptake and increased glycogen stores. If 
this were the case, one would expect better muscle performance. We tested this by 
investigating the in vitro resistance to fatigue by measuring the force developed after repeated 
stimulation of EDL (tetanic stimulation with a frequency of 70Hz, 300msec duration) and 
soleus muscles (tetanic stimulation with a frequency of 50Hz, 600msec duration) isolated 
from mice kept on a low vitamin A diet for two generations. In the presence of insulin, soleus 
muscles from SRP35TG showed a significant increase of about about 50% (p< 0.05, n= 5 WT 
and 5 SRP35TG) of the force remaining after tetanic stimulation (Fig. 6F). EDL muscles also 
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showed a significant resistance to fatigue, though the difference between WT and SRP35TG 
mice was not as pronounced (Fig. 6E) The resistance to fatigue is likely due, at least in part, 
by the size of the glycine stores. Indeed, after the fatigue protocol the glycogen content of 
EDL (Fig. 6G) and soleus (Fig. 6H) muscles from SRP35TG mice kept on a low vitamin A 
diet was significantly higher than that of muscles from WT mice kept on a low vitamin A diet. 
It should also be pointed out that the glycogen stores in EDL and soleus muscles were smaller 
after the fatigue protocol compared to the glycogen stores present in unstimulated muscles 
(compare Fig.3B to Fig. 6G and H)). 
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DISCUSSION 
The present study demonstrates that the skeletal muscle protein SRP-35, a retinol 
dehydrogenase, is directly involved in skeletal muscle metabolism, since its over-expression 
results in higher glucose uptake and increased glycogen storage. In addition, SRP-35 over-
expression improves muscle performance in vivo, an effect which occurs in the absence of 
changes in the ECC machinery. We also provide compelling evidence as to the mechanism by 
which SRP-35 leads to the increased glucose uptake in skeletal muscle. In particular we show 
that SRP35TG mice have an up-regulation of the signaling pathway involving AKTS473 
phosphorylation via activation of mTORC2. Pharmacological application of atRA to intact 
muscles from WT mice mimics the stimulation of AKTS473 phosphorylation observed in 
SRP35TG muscles, while inhibitors of the RARα and RARnuclear receptors inhibit 
AKTS473 phosphorylation in WT muscle treated with pharmacological concentrations of atRA.  
On the basis of these results we believe that AKTS473 phosphorylation in skeletal muscles of 
SRP35TG mice is linked to the enzymatic activity of SRP-35 which produces locally within 
the muscle, all-trans-retinaldehyde, the precursor of the irreversible oxidation reaction leading 
to atRA formation. Altogether these data support a role for retinoic acid as the biological 
mediator of the metabolic response responsible for the enhanced muscle function of 
SRP35TG mice. Figure 7 shows a schematic representation based on the results of the present 
investigation, of the cellular pathways involving SRP-35 and retinoic acid metabolism in 
skeletal muscle. 
Overexpression of SRP-35 and atRA increase AKTS473 phosphorylation. 
Activation of AKT is due to phosphorylation of Thr308 and Ser473 by phosphinositide-
dependent protein kinase 1 (PDK1) and mTORC2, respectively (29, 31, 36). Overexpression 
of SRP-35 in skeletal muscle selectively increases the phosphorylation of the mTORC2-
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dependent AKT phosphorylation site AKTS473 and this occurred both in isolated EDL and 
soleus muscles from SRP35TG in the presence and absence of insulin. This implies that: (i) 
chronic over-expression of SRP35 in skeletal muscle increases the basal AKTS473 
phosphorylation level, and (ii) the atRA generated by the irreversible oxidation all-trans-
retinaldehyde, acts as a co-activator of the insulin signaling pathway leading to AKTS473 
phosphorylation. This conclusion is also supported by a separate set of data showing that 
atRA mimics the effect of SRP-35 overexpression. Indeed, treatment of EDL muscles from 
WT mice with pharmacological concentrations of atRA enhanced insulin-induced AKTS473 
phosphorylation levels. At variance with what was observed in EDL muscles isolated from 
SRP35TG mice however, incubation of EDL from WT mice with atRA in the absence of 
insulin did not result in AKTS473 phosphorylation. Our results differ from those showing that 
in a variety of cells types including A549, F9 and HL-60 cells, atRA alone is able to induce 
AKT phosphorylation (37-39). These apparent discrepancies may be due to: (i) different 
experimental models, cofactors and proteins present in the cell culture medium (40); (ii) the 
lack in the EDL from WT mice of the adaptive changes induced by SRP-35 over-expression 
leading to an alteration of the atRA level within a subdomain of the muscle fibre. 
Nevertheless the present study demonstrates that atRA plays a newly identified role in the 
modulation of cellular functions downstream AKTS473 phosphorylation, including glucose 
metabolism.  
SRP-35 and atRA activate mTORC2 signaling 
Under physiological conditions mTORC2 is the major kinase responsible for the 
phosphorylation of AKTS473 (29). In the presence of DNA damage AKT can also be 
phosphorylated at Ser473 by DNA-dependent protein kinase (DNA-PK) (41). Skeletal muscle 
fibres from SRP35TG mice do not show evidence of nuclear damage (not shown) and thus we 
exclude the possibility that AKTS473 phosphorylation is mediated by DNA-PK. In fact our 
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results on RImKO mice strongly support the participation of mTORC2 in the SRP-35/atRA 
signaling pathway. In the present study we show that atRA is unable to reverse the inhibitory 
effect of Rictor ablation on the phosphorylation levels of AKTS47 in insulin stimulated skeletal 
muscles (32). This result provides unambiguous evidence that mTORC2 activation is a key 
component of SRP-35/atRA signaling.  
atRA: an  enhancer of  insulin signaling. 
atRA acts as an enhancer of insulin signaling since it enhances AKTS473 phosphorylation 
beyond that caused by the activation of the insulin receptor. The latter is coupled to the 
stimulation of PI3K activity which in turn leads to an increase of PIP3 on the plasma 
membrane, a crucial step for the recruitment of AKT onto the plasma membrane where it is 
phosphorylated by PDK1 and mTORC2. AKT phosphorylation mediates the metabolic effects 
of insulin, leading to the translocation of GLUT4 onto the plasma membrane and stimulating 
glucose uptake. Both atRA and SRP-35 over-expression synergize with insulin on the insulin 
dependent AKTS473 phosphorylation. The RA resulting from the oxidation of all-trans-
retinaldehyde, the precursor of retinoic acid generated by the up-regulation of the SRP-35 
dehydrogenase activity could synergize with insulin at different steps of the insulin signaling 
pathway. The data presented in this study provides insight as to one such possible mechanism.  
In particular, we found that:  (i) skeletal muscles from SRP35TG mice have a 14 fold increase 
of the PIP3 content and (ii) manipulation of the myoplasmic concentration of atRA with a low 
Vitamin A diet affects the PIP3 content of skeletal muscle. Previous work has shown that 
inhibitors of RAR nuclear receptors down-regulate PI3K activity, the enzyme responsible for 
the synthesis of PIP3. On the basis of these data and on our own results demonstrating that the 
AKTS473 phosphorylation is prevented by RAR and RAR inhibitors, we believe that the 
increase of PIP3 content in skeletal muscle from SRP35TG results from a non-genomic effect 
of atRA on PI3K activity (42, 43). Accumulation of PIP3 in skeletal muscle membranes 
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results in the recruitment and activation of mTORC2 kinase leading to the phosphorylation of 
AKTS473.   
SRP-35 improves muscle performance by increasing glucose uptake and glycogen store. 
Over-expression of SRP-35 in skeletal muscle leads to a remarkable improvement of the in 
vivo muscle performance, both in young and old (7 and 14 months old, respectively) mice. 
This effect could be due to a (i) gain of function of the ECC mechanism, (ii) fast to slow 
fibre-type switching, (iii) adaptive metabolic changes, or (iv) a combination of two or more of 
these mechanisms. Our results exclude the first possibility because we did not observe 
changes of the mechanical properties of EDL and soleus muscles. Additionally, the enhanced 
muscle performance is not linked to changes in the fibre type composition because there was 
no evidence of fibre type switching in either EDL or soleus.  Both type I and type II fibres is 
soleus muscle from SRP35TG mice undergo a 10 % increase of the minima Ferret’s diameter. 
The increase of AKTS473 phosphorylation may account for this small hypertrophy (44) of 
soleus muscles in SRP35TG mice and this is also consistent with the enhanced running 
capacity (45).  Nevertheless, such a modest hypertrophy cannot fully account for the enhanced 
running capacity observed in SRP35TG mice. In fact our results indicate that the enhanced 
muscle performance is linked to glucose metabolism. Under basal conditions, skeletal muscles 
from SRP35TG mice display a specific increment in GLUT4 translocation onto the 
sarcolemma and T tubules and this is accompanied by higher glucose uptake even in the 
absence of insulin. Expression and activation of GLUT4 depends on a variety of stimuli, 
including RA. Indeed treatment of the L6 muscle cell lines with atRA enhanced insulin-
stimulated glucose uptake and increased GLUT4 expression to plasma membrane (22). 
Activation of the insulin receptor stimulates PI3K activity which ultimately leads to GLUT4 
translocation onto plasma membrane by the activation of two parallel signaling cascades: 
AKT phosphorylation and Rho-family small GTPase Rac1. Our results show that in 
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SRP35TG mice the increased plasma membrane GLUT4 is linked to an increase of AKTS473 
phosphorylation. The latter in turn leads to larger glycogen stores in skeletal muscle. This 
adaptive mechanism in SRP35TG mice is accompanied by an increase in glycogen 
phosphorylase (GP), the enzyme initiating the breakdown of glycogen to glucose-1-phosphate 
during prolonged skeletal muscle activity (7). We are confident that the longer running 
distance observed in SRP35TG mice is explained by the mechanism described above. 
Altogether, our results unravel a novel aspect of RA signaling in skeletal muscle and raise the 
possibility that SRP-35 maybe targeted to affect glucose metabolism in patients with 
metabolic disorders. 
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METHODS 
SRP-35 transgenic mice- The transgenic mouse line (generated in the Transgenic Animal Facility 
of Basel University) was constructed by inserting the mouse SRP-35 cDNA downstream the muscle 
specific creatine kinase promoter to target expression to skeletal muscle. Supplementary figure 1 
shows a schematic representation of the construct used to create the SRP-35 over-expressing mice 
(SRP35TG) and a representative PCR analysis of the genomic DNA from several mouse lines 
generated after pronuclear injection. Mice were genotyped by PCR using genomic DNA, the following 
primers: 5`- GTAGCTTTTCCTGTCAATTCTGCC-3`(forward) and 5`- 
GAGCCCCATGGTGAAGCTT- 3`(reverse) and conditions: GoTaq G2 DNA polymerase (Promega; 
Madison, USA) and the following amplification protocol, 1 cycle at 95°C for 5 min followed by 38 
cycles of annealing (62°C for 30 s), extension (72°C for 30 s) and denaturation (95°C for 30 s), 
followed by a 7 min extension cycle at 72°C.  A total of three SRP35TG mouse lines expressing the 
transgene to different levels were obtained. Since mouse line N°5 expressed the highest SRP-35 TG 
levels, the experiments described in this paper were carried out on this line and confirmed in the other 
two lines.  
mTORC2 KO (RImKO) mice: 3 months old male muscle-specific rictor knockout mice 
(RImKO) were obtained from Prof. M. Rüegg`s and Prof. M. Hall’s laboratories (31).   
Special diet- WT and SRP35TG mice were fed a Low Vitamin A Diet (LVAD; 4 UI/g; 
Scientific Animal food and Engineering) for 2 generations. The mice of the second generation 
were sacrificed at 4 months of age (35). 
In vivo and in vitro assessment of muscle function- In vivo muscle function was assessed 
using the voluntary running wheel on 7 and 14 months old male mice as previously described 
(46). For in vitro assessment of muscle function, force measurements were assessed using a 
force transducer (MyoTonic, Heidelberg), and by measuring the force generated in response 
to different protocols including a single twitch (15 V pulses for 0.5 ms duration) and tetanic 
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frequency pulses (50, 100 and 150 Hz) in soleus (slow muscle) and (50, 100 and 200 Hz) in 
extensor digitorum longus (EDL, fast muscle). Resistance of muscle to fatigue was also 
measured in EDL and Soleus muscles isolated from WT and SRP35TG mice kept for 2 
generations on a low Vitamin A diet; muscles were incubated in Krebs Ringer containing 100 
nM insulin, and stimulated electrically using a fatigue protocol (EDL: 300 ms duration, 70 Hz 
and 0.33 Hz of time between stimulus (tbs); Soleus, 600 ms duration, 50 Hz frequency and 
0.33 Hz of tbs) as described (Johansson et al. 2003). 
Basic metabolic rate- The metabolic rate of WT and TG (7 months old) male mice was 
assessed by indirect calorimetry using a Comprehensive Lab Animal Monitoring System 
(Oxymax/CLAMS; Columbus Instruments, Columbus, OH, USA). Following an initial 48 h 
acclimatization, mice were monitored every 17 min for 24 h for a complete 12 h active (dark) 
and 12 h inactive (light) cycle. Oxygen consumption (VO2), CO2 production (VCO2), physical 
activity, heat production and respiratory exchange ratio (RER = V˙CO2 /VO2) were measured 
during 72 hours. 
Histological examination, changes in muscle fiber type and glycogen content- Calculation 
of the minimal Feret’s diameter, the closest possible distance between the two parallel 
tangents of an object, was determined as described (46). Images were obtained using an 
Olympus IX series microscope and analyzed using the CellP Software. The fiber type 
composition was assessed by determining the expression of different myosin heavy chain 
isoforms by high resolution gel electrophoresis followed by Coomassie Brilliant blue gel 
staining as described (47, 48). 
Glycogen content was assessed enzymatically on snap frozen EDL and soleus muscles using a 
hexokinase-dependent, kit according to the manufacturer's instructions (GAHK-20, Sigma-
Aldrich; USA). A control to measure free glucose levels in the muscle (not related to 
glycogen stores), was also performed.  
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Gel electrophoresis and western blotting- Total homogenates, sarcoplasmic reticulum (SR) 
and skeletal muscle subcellular fractions longitudinal sarcoplasmic reticulum (LSR) and 
terminal cisternae (TC), were prepared as described (25). Protein concentration was 
determined using a kit from BioRad (Bio-Rad, 500-0006) using bovine serum albumin as 
standard; proteins were separated on SDS-PAG gels, transferred onto nitrocellulose 
membranes and probed with commercially available antibodies. Immunopositive bands were 
visualized by chemiluminescence. 
Signaling pathways involved in glucose uptake: AKT and AMPK phosphorylation- Isolated 
soleus muscles from 28 weeks old mice were used to determine the levels of AKT and AMPK 
phosphorylation. Muscles were homogenized in lysis buffer (10% Glycerol, 5% β-
mercaptoethanol, 2.3 % SDS, 62.5 mM Tris-HCl pH 6.8 and 6 M urea, supplemented with 1 
% phosphatase inhibitor cocktails 2 and 3 Sigma Aldrich) at a concentration of 10 mg of 
muscle/ml buffer. Subsequently, 50 µg of protein were separated on a 10% SDS PAG, 
transferred onto nitrocellulose (Amersham), and probed with the following primary 
antibodies: phospho-AMPK (Thr172), AMPK alpha, phospho- AKT (ser 473), phopho-Akt 
(thr 308) and AKT total from Cell Signaling and Desmin (used as housekeeping loading 
control) from Santa Cruz. The intensity of the immunopositive bands was determined using 
Image J.  
Glucose Uptake- Glucose uptake by isolated EDL and soleus muscles was measured in 
isolated muscles incubated for 1h at room temperature in Krebs-Ringer buffer supplemented 
with 1 mM glucose, 10 mM sodium pyruvate and 0.5% bovine serum albumin. The medium 
was continuously gassed with 95% O2 and 5% CO2. For electrical stimulation, muscles were 
stimulated with a 300 ms train of action potentials of 0.5 ms duration at a frequency of 80 Hz 
by using a stimulator (Myotronic, Heidelberg Germany); the 300 ms trains of action potentials 
were delivered for a 5 min at a frequency of 0.27Hz. For insulin stimulation, muscles were 
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incubated in the presence or absence of insulin (100 nM; Novo Nordisk Pharma AG; 
Bagsværd, Denmark) for 10 min at room temperature. Contralateral non-stimulated muscles 
were used as controls. Stimulated or control muscles were then incubated with 0.375 µCi/ml 
Deoxy-D-glucose, 2-[1,2-
3
H (N)] (2-[
3
H]-DG (Perkin Elmer, Waltham, MA) for an additional 
20 min at room temperature, flash frozen and stored in liquid nitrogen until ready for use. The 
amount of radioactive glucose taken up by the muscles was assessed by liquid scintillation 
counting, using a Packard 1900 TR liquid scintillation analyzer. 
Glucose and insulin tolerance tests- For the glucose tolerance test (GTT), following a 6 h 
fast and starting in the morning, mice were injected intraperitoneally with a glucose-
containing solution (1 µg glucose/g of body weight). Glucose plasma levels were determined 
at different time points (0, 15, 30, 60 and 90 min) using a glucometer (Freestyle; Abbott 
Diabetes Care Inc., Alameda, CA; USA). Insulin plasma levels were determined at different 
time points (0, 15 and 30 min) using an insulin ELISA kit (Mercodia; Uppsala, Sweden) 
following the manufacturer’s recommendations. 
Effect of all-trans-retinoic acid (atRA)-EDL and soleus muscles from 28 weeks old WT 
mice, were cleaned in a Ringer solution continuously gassed with 95% O2 and 5% CO2 at 
room temperature. The muscles were incubated in the presence or absence of 10 µM All-
trans-retinoic acid (atRA, dissolved in DMSO; Sigma), control muscle were incubated with 
the vehicle DMSO. After 30 or 60 min of incubation, the muscles were washed and stored in 
liquid N2. In some experiments insulin (100 nM) was also added to the muscles incubated 
with atRA and the controls. The muscles were homogenized; proteins separated by 
SDS/PAGE and transferred to a nitrocellulose membranes. Phosphorylation sites and total 
protein content of AMPK and AKT were analyzed. All experiments were performed under 
red light illumination. 
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Effect of Retinoic acid Receptor (RaR) inhibitors- EDL and soleus muscles isolated from 
WT mice were incubated in Ringer’s solution containing one of 3 different RAR inhibitors 
(RARα, RARβ or RARγ inhibitors), 100 nM insulin and in presence or absence of 10 µM 
atRA. Muscles from the contralateral leg were taken as controls and incubated with the same 
RAR inhibitor as their counterpart muscles, together with100 nM insulin and DMSO. After a 
30 min incubation with the RARα inhibitor Ro 41-5253 (50 nM; Sigma), RARβ inhibitor LE 
135 (220 nM; Sigma) or RARϒ inhibitor Acacetin (30 uM; Sigma), insulin and atRA/DMSO, 
the muscles were flash frozen in liquid N2 and subsequently analysed by western blotting for 
AKT and AMPK phosphorylation. All experiments were performed under red light 
illumination. 
PIP3 measurements- PIP3 levels were measured in muscles of WT and SRP35TG mice fed a 
standard chow or a low vitamin A diet. Freshly isolated EDL muscles were flash frozen in 
liquid N2 and ground using a pestle and mortar. Lipids were extracted from the powdered 
muscles and PIP3 content was assessed as previously described (49) using the PIP3 Mass 
ELISA kit (K-2500s, Echelon, USA). 
Animal permits- All experiments were conducted according to the Swiss Veterinary Law and 
institutional guidelines and were approved by the Swiss authorities (Kantonal permits 1728 
and 2115). All animals were housed in a temperature-controlled room with a 12 h light–12 h 
dark cycle and had free access to food and water. 
Statistical analysis- Statistical analysis was performed using the software OriginPro 8.6.0 
(OriginLab Corporation). Comparisons of two groups were performed using the Student's t-
test, for groups of three or more comparisons were made using the ANOVA test followed by 
the Bonferroni post-hoc test unless otherwise stated. Means were considered statistically 
significant when P values were < 0.05. All figures were created using Adobe Photoshop CS6 
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or R Studio (version 0.99.891 or newer). For non- parametric results, the Man Whitney test 
was used.  
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FIGURE LEGENDS 
Figure 1: Spontaneous activity, fiber type composition, force measurements and SR 
protein composition of muscles from SRP35TG mice. (A) Spontaneous daily activity of 
WT (white symbols; n=16) and SRP35TG (black symbols; n=16) mice. Data points from 7 
months (left) and 14 months (right) old mice are expressed as mean (±S.D.), ***p <0.001 
Mann–Whitney test. (B) Dark phase speed events recorded from the 15th to 20th day of 
running (mean ±S.D., n=16). (C) and (D) Fibre type composition Minimal Ferret’s diameter 
determined by myosin-heavy chain (MyHC) immunohistochemistry in EDL and soleus 
muscles of slow (MyHCI) and fast (MyHCII) fibres (mean±S.D., n= 10, *p<0.05 Student’s t 
test). (E) Fibre size distribution of EDL and soleus muscles from WT and SRP35TG mice 
(mean ±S.D., n=10). (F) Mechanical properties of EDL and soleus muscles from WT 
(continuous line, representative trace of experiments carried out in 7 mice) and SRP35TG 
(dashed line, representative trace of experiments carried out in 13 mice) mice. Twitch force 
stimulated by a 15 V pulse of 0.5ms duration. Maximal tetanic force induced by a train of 
pulses delivered at 150 and 120 Hz for EDL and soleus, respectively. (G) Western blot 
analysis. Thirty-five µg of total SR protein were loaded per lane, separated on 6% or 10% 
SDS/PAGE. Bar histograms represent the mean (±S.D.) intensity of the immunoreactive band 
in SRP35TG fraction expressed as % of the intensity of the band in WT mice (n=6, **p<0.01 
Student’s t test).  
Figure 2: Glucose uptake and plasma membrane GLUT4 levels are increased in 
SRP35TG mice. (A) Glucose tolerance test (ipGTT) in WT (n=8) and SRP35TG (n=8) mice, 
values are expressed as mean (±S.D.) blood glucose levels; *p<0.05; **p<0.01 Student’s t 
test. (B) Circulating insulin in WT (n=8) and SRP35TG (n=8), is expressed as mean (±S.D.) 
pg of insulin measured after glucose injection. Values were not significantly different in WT 
and SRP35TG mice (Student’s t test). (C) GLUT4 content of total SR and R1 fraction (tubule 
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T/sarcolemma membranes) of skeletal muscles from wild type (wt; n=8) and SRP3TG (tg; 
n=8) mice. Ten µg of protein were loaded per lane and separated on 7.5% SDS/PAGE (left); 
bar histograms of GLUT4 content in skeletal muscles from SRP35TG (black bars), 
normalized to control levels (white bars). Results are expressed as mean ±S.D., **p<0.01; 
***p<0.001 Student’s t test. (D) Western blot of GLUT4 in total homogenate from EDL and 
soleus muscles. 
Figure 3: Skeletal muscle glycogen stores and RER in SRP35TG mice. (A) In vitro 
glucose uptake in EDL and soleus muscles from WT and SRP35TG. Three conditions were 
used: (i) no treatment (Basal; n=8); (ii) 10 min incubation with 100 nM insulin (n=6), (iii) 
electrical stimulation with a train of tetani (80 Hz, 300 ms duration) delivered at 0.27 Hz for 5 
min (n=6). Data is expressed as mean (±S.D.); *p<0.05; **p<0.01 Student’s t test. (B) 
Glycogen content was assessed enzymatically in total homogenates from EDL and soleus 
muscles. Each symbol represents the mean value of both muscles of a single mouse; the 
median value is represented by the horizontal black line; *p<0.05 Student’s t test. (C) 
Respiratory exchange ratio (RER) was measured in CLAMS cages in WT (n=8) and 
SRP35TG (n=8) mice, fed a standard chow diet. Values are expressed as mean (±S.D.); 
*p<0.05 Student’s t test. (D) Spontaneous locomotor activity was recorded on X, Y and Z 
axis, and is expressed as mean infrared beam breaks (±S.D.); n=8, *p<0.05 Student’s t test. 
Figure 4: AMPK and AKT phosphorylation levels are increased in muscles from 
SRP35TG mice. Western blots of total homogenates from EDL and soleus muscles. 
Phosphorylation of AMPKT172 and AKTS473 was determined under the following experimental 
conditions. (A) and (B) basal conditions (n=7). (C) and (D) electrical stimulation with a train 
of  tetani  (80 Hz, 300 ms duration) delivered at 0.27 Hz for 5 min (n=6). (E) and (F) 
stimulation  with 100 nM insulin (n=6). Representatives western blots from the three 
conditions are show in panels A, C and E and the Bar histograms in panels B, D and F. Fifty 
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µg of protein from total muscle homogenates were loaded per lane, separated on 10% SDS-
PAGE and blotted onto nitrocellulose. The immunoreactivity to desmin was used to normalize 
protein loading. Data are presented as % (±S.D.) of WT values (control); *p<0.05 Student’s t 
test. 
Figure 5: atRA activates AKTS473 phosphorylation in WT EDL and soleus muscles. Fifty 
µg of protein from total muscle homogenates were loaded per lane, separated on 10% SDS-
PAGE and blotted onto nitrocellulose. The immunoreactivity to desmin was used to normalize 
gel loading. Data are presented as % (±S.D.) of control (empty bar); * p<0.05 Student’s t test. 
AMPKT172, AKTS473 and AKTT308 phosphorylation levels were measured by western blotting 
on total homogenates from EDL and soleus with specific anti-phospho Ab. (A) and (C) 
Skeletal muscles isolated from WT mice were incubated with 10 μM all-trans-retinoic acid 
(atRA, bars; n=6). Control values (empty bar) were obtained by incubating the contralateral 
muscle in the presence of the vehicle solution (DMSO). (B) and (D)  EDL and soleus muscles 
incubated with 100 nM insulin plus or minus 10 μM atRA. Left side: representative western 
blots at 30 min of incubation; right side: bar histogram plots, (n=6 *p<0.05 Student’s t test). 
Control values (empty bar) for normalization were obtained by performing the experiments in 
the presence of 100 nM insulin plus vehicle (DMSO). (E) and (F) EDL muscles were 
incubated for 10 min in presence of 100 nM insulin, RARα, RARβ and RARγ inhibitors plus 
or minus 10 μM atRA. Control values (empty bar) were obtained in the presence of 100 nM 
insulin, plus the RAR inhibitor. Data are presented as mean ±S.D., n=6, *p<0.05 Student’s t 
test.  
Figure 6: SRP-35 and atRA activation of AKTS473 is controlled by mTORC2 and the 
PI3K signaling pathway. (A) and (B) Western blot images and bar histograms showing the 
phosphorylation of AKT in EDL and soleus muscles from WT (n=5) and RimKO (n=5) mice 
incubated with or without 10 μM atRA in presence of 100 nM insulin. Fifty µg of total 
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homogenate protein were loaded per lane, separated on 10% SDS/PAGE and blotted onto 
nitrocellulose. Anti-desmin immunoreactivity was used as loading control (bars represent the 
mean ±S.D., *p<0.05 Student’s t test). (C) PIP3 levels from EDL muscles isolated from WT 
and SRP35TG mice fed a standard chow diet (Top panel) and on a low vitamin A diet (LVA, 
4 I.U/Kg, Bottom panel). Each symbol represents PIP3 values from a single mouse; the 
median value of the data is shown in the box-plot; n.d= non detectable (muscles from 7 mice) 
*p<0.05 Mann Whitney test. (D) PIP3 levels from soleus muscles isolated from WT and 
SRP35TG mice fed a standard chow diet (Top panel) and on a low vitamin A diet (LVA, 4 
I.U/Kg, Bottom panel). Each symbol represents PIP3 values from a single mouse; the median 
value of the data is shown in the box-plot; *p<0.05 Mann Whitney test. (E) EDL muscles 
from WT (closed squares) and SRP35TG (closed triangles) mice kept for 2 generations under 
low Vit A diet (LVA), were electrically stimulated in the presence of 100 nM insulin using a 
fatigue protocol (70Hz, 300 ms duration, delivered at 0.33Hz) and the force generated (% of 
initial force) at the indicated times was calculated. Each point represents the mean (±S.D.; n= 
5 WT and 5 SRP35TG) force; P<0.05 Mann Whitney. (F) Soleus muscles from WT (closed 
squares) and SRP35TG (closed triangles) mice kept for 2 generations under low Vit A diet 
(LVA), were electrically stimulated in the presence of 100 nM insulin using a fatigue protocol 
(50Hz, 600 ms duration, delivered at 0.33Hz) and the force generated (% of initial force) at 
the indicated times was calculated. Each point represents the mean (±S.D.; n= 5 WT and 5 
SRP35TG) force; P<0.05 Mann Whitney. (G) Glycogen content was assessed enzymatically 
in total homogenates from EDL muscles at the end of the fatigue protocol. Each symbol 
represents the value from a single mouse; the median value of the data is shown in the box-
plot; *p<0.05 Mann Whitney test. (H) Glycogen content was assessed enzymatically in total 
homogenates from soleus muscles at the end of the fatigue protocol. Each symbol represents 
the value from a single mouse; the median value of the data is shown in the box-plot; *p<0.05 
Mann Whitney test. 
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Figure 7: Schematic representation of the SRP-35 pathway and its effect on glucose 
metabolism. SRP-35 transforms retinol to retinal and the latter is converted to retinoic acid. 
In the presence of insulin, retinoic acid activates the Retinoic Acid Receptor α and γ (RARα 
and RARγ)/ Phosphoinositide 3-kinase (PI3K)/ mTOR Complex 2 (mTORC2)/ AKTS473. 
Activation of AKT induces the downstream translocation of GLUT4 onto the sarcolemma 
leading to higher glucose uptake by muscles which in turn leads to greater glycogen stores 
giving the skeletal muscle machinery a higher energy source.
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2.2 Additional Unpublished Data 
Effect of insulin and low vitamin A diet on glycogen content and fatigue 
resistance of muscles from SRP35TG mice. 
Vitamin A (retinol) is a fat-soluble vitamin made up of a 20 carbon structure with a methyl 
substituted cyclohexenyl ring (beta-ionone ring) which is essential for vision, gene 
expression, reproduction, embryonic development, growth, and immune functions. Humans 
need to take in retinol with their diet by consuming fish, meat, colored fruits, yellow tubers 
and dark green leafy vegetables (O'Byrne and Blaner, 2013). The effect of vitamin A dietary 
concentrations have a big impact on retinoic acid production in mammals. Experiments 
carried out in different mice strains in which animals were fed with diet containing two 
different Vitamin A concentrations for 3 generations, show that the concentration of several 
retinoids, including retinoic acid (RA), varies depending on the dietary Vitamin A 
concentration (Obrochta et al., 2014). Mice fed with Low Vitamin A diet (4 IU vitamin A, 
LVAD) present a lower RA concentration in several tissues including liver, kidney, testis, 
white adiposity tissue and serum compared with mice fed with standard Chow diet (12 to >20 
IU vitamin A) (Obrochta et al., 2014).  
Additionally, several groups have shown that the diet is able to mask the phenotype of 
genetically modified animals, specifically, Chow diets containing a higher concentration of 
vitamin A, prevent the manifestation of specific phenotypes which would result from ablation 
of genes that modulate retinoid homeostasis (Obrochta et al., 2014). Experiments with retinol‐
binding protein (RBP) knockout mice (RBP
−/−
) fed with a Chow diet presented no dramatic 
phenotype changes compared to wild type littermates, but RBP
−/−
 mice fed with LVA diet 
showed clear developmental and reproduction problems (Quadro et al. 1999). Similar results 
were found in Cellular retinol-binding protein II-null (CRBP II −/−) mice fed with Chow diet; 
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such mice had no overt phenotype, however under LVA diet the CRBP II −/− mice had a 
100% mortality/litter within 24 h after birth (E et al., 2002). Another interesting result was 
reported in retinol dehydrogenase 1 (rdh1)-null mice. Such mice fed with a normal diet did 
not exhibit any significant changes compared to their WT littermates, however th KO mice 
fed with LVA diet showed higher body weight and adipocytes (Zhang et al., 2007). 
In order to test the impact of dietary Vitamin A concentrations on the phenotype of SRP35TG 
mice, we fed these mice for 2 generations with a LVA diet. Muscles isolated from SRP35TG 
mice under Chow or LVA diets were compared for various parameters, including their 
resistance to fatigue and glycogen content. The results of these studies will be illustrated in 
the next sections of my thesis.  
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Effect of LVA diet and insulin on the fatigue resistance of EDL 
and Soleus muscles from SRP35TG mice. 
In the present section we describe the effects of two different concentrations of dietary 
vitamin A in the presence or absence of insulin on the fatigue resistance and glycogen content 
of EDL and soleus muscles from SRP35TG and WT mice. In addition to the in vitro fatigue 
resistance test and glycogen content performed on EDL and soleus muscles from SRP35TG 
and WT mice (fed for 2 generations with LVA diet), we also tested fatigue resistance and 
glycogen content of muscles isolated from mice under standard Chow diet. It is important to 
keep in mind that the aim of feeding the mice with the LVA diet is based on the hypothesis 
that at any given intracellular retinol concentration, muscle fibres over-expressing SRP-35 
would generate greater amounts of all-trans-retinaldehyde (precursor of atRA formation). 
Therefore, SRP35TG mice fed with a LVA diet should be able to generate more atRA 
compared to WT littermates and enhance even more PI3K activity. This enhanced enzymatic 
activity should enhance mTORC2/AKT signaling which in turn may lead to higher glucose 
uptake and increased glycogen stores, leading to better muscle performance compared to WT 
mice. The experiments were conducted on muscles incubated with insulin (100 nM) because 
in our previous observations (presented in the paper) we showed that insulin is necessary to 
induce the non-genomic effect of RA on AKTS473 phosphorylation. 
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Figure R3.1- Fatigue resistance in muscles from SRP35TG mice maintained on a LVA 
diet. EDL and Soleus muscles from WT (open squares) and SRP35TG (closed squares) mice 
were stimulated with a train of tetanic stimulation (EDL: 70 Hz, 300 ms duration; Soleus 
50 Hz, 600 ms duration) delivered at 0.33 Hz. Maximal specific force (mN/mm2) of the first 
tetanic contracture is expressed as 100%. Four different conditions were tested: Muscle from 
SRP35TG and WT mice (A) under Chow diet; (B) under Chow diet and incubated with 
insulin (100 nM); (C) under   LVA diet; (D) and under LVA diet and in the presence of 
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insulin (100 nM).  Each point represents the mean ± S.D.; n = 5 WT and 5 SRP35TG; 
*p < 0.05 Mann-Whitney. 
 
As demonstrated by Quadro et al. and Zhang et al., in genetically modified mice fed with 
different amounts of Vitamin A (Quadro et al., 1999; Zhang et al., 2007; Obrochta et al., 
2014), the effect of the LVA diet on the mouse`s phenotype is dramatic. The results depicted 
in Figure R3 show that under a Chow diet no significant difference in force generated by 
muscles from WT and SRP35TG mice were observed. However, under LVA diet, the soleus 
muscles of SRP35TG mice exhibited a higher resistance to fatigue compared to WT 
littermates (Figure R3.1 panel A and C). Interestingly, EDL muscles did not show any 
significant difference in their fatigue resistance in WT and SRP35TG mice under Chow diet. 
This effect could be related to the fibre type composition; in fact EDL (Fast-twitch) muscles 
express a higher proportion of fast speed fibre types (MyHC type I: 0.4 %; type IIA, type 
IIDB 21.4 %; and type IIB 66.0 %), compared to soleus (slow-twitch) muscles, which contain 
a mixute of slow and fast fibre types (MyHC type I: 37.4 %; type IIA: 38.6; type IIAD: 18.7 
%) (Augusto et al., 2004). This difference in fibre type composition is very important in 
muscle performance, due to the specific protein expression characteristics of each MyHC 
type. Firstly, MyHC type I fibres show a slower rate of cross-bridge cycling and ATP 
consumption compared to MyHC type II. Secondly, MyHC I fibres express the SERCA type 
2 isoform to a lower density compared to MyHC II fibers, where SERCA 1 is highly 
expressed. Thirdly, the protein parvalbumin is almost exclusively expressed in MyHC II 
fibres, but is almost undetectable in MyHC I fibres. (Füchtbauer et al., 1991; Biral et al., 
1992; Bottinelli and Reggiani, 2000; Calderon et al., 2014). Finally, the fast type II fibres 
(with a higher ATP consumption) are endowed with a higher anaerobic metabolism and lower 
oxidative capacity that allows them to have short explosive movements, but with a low 
resistance to fatigue (Westerblad et al., 2010; Argilés et al., 2016). Thus, in order to clarify 
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the mechanism leading to the different fatigue responses between EDL and Soleus muscles 
from SRP35TG mice under LVA diet more detailed investigations are required and these 
could be the aim of future studies. 
While performing the experiments included in my thesis we also discovered that the presence 
of insulin is a necessary requirement to observe a non-genomic effect of RA. Skeletal muscle 
from SRP35TG mice under Chow diet did not present any significant change in fatigue 
resistance, however EDL and soleus muscles obtained from SRP35TG mice kept under a 
Chow diet, and incubated with insulin (100 nM) during the experimental procedure, exhibited 
a slightly better performance compared to muscles from WT mice (figure R31. Panel B). 
Interestingly, muscles from SRP35TG mice under LVAD and in the presence of insulin (100 
nM) showed the largest difference in fatigue resistance for both EDL and soleus muscles 
compared to muscles from WT mice also fed wit LVA diet (figure R3.1 panel D).  
As mentioned previously glycogen storage is a very important role played by skeletal muscle; 
indeed glycogen is a form of stored, energy which allows the muscle to respond rapidly to any 
environmental signal when glucose is not available, making this tissue an important player for 
whole body metabolism (Argilés et al., 2016). Figure R3.2 panel A and C show that the levels 
of glycogen stores in mice fed with the LVA diet, decreased significantly both in WT mice 
and SRP35TG mice. However, SRP35TG mice still exhibit higher glycogen stores under all 
tested conditions (Figure R3.2). These results indicate that SRP-35 is directly involved in the 
regulation of glycogen stores in skeletal muscle. In line with this result it should be remember 
that EDL and soleus muscles from SRP35TG mice exhibit higher glucose uptake which in 
turn would facilitate the maintenance of larger glycogen stores in muscles from SRP35TG 
mice compared to WT mice.  
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Figure R3.2- Glycogen content.  EDL and Soleus muscles from WT (open squares) and 
SRP35TG (closed squares) mice were stimulated with a train of tetanic stimulation (EDL: 
70 Hz, 300 ms duration; Soleus 50 Hz, 600 ms duration) delivered at 0.33 Hz. Glycogen 
content was assessed enzymatically in muscle total homogenate. Four different conditions 
were tested: Muscle from SRP35TG and WT mice (A) under chow diet; (B) under Chow diet 
and incubated with insulin (100 nM); (C) under   LVA diet; (D) and under LVA diet and in 
presence of insulin (100 nM). The median value of the data is shown in the box-plot; 
*p < 0.05 Mann-Whitney test. 
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In conclusion, our results show that the higher vitamin A levels of Chow diet might mask the 
phenotype of SRP-35 overexpression in skeletal muscle. However, our results unambiguously 
show that SRP35TG mice fed with a LVA diet exhibit a higher fatigue resistance compared to 
WT littermates mice and the presence of insulin in the solution bathing the isolated skeletal 
muscles further increased the difference between these two groups of mice. The lack of a 
significant differences between WT and SRP35TG mice fed with Chow diet could be due to 
the fact that large amount of dietary vitamin A may allow the synthesis of atRA by pathways 
independent of retinoid-chaperoning proteins (Obrochta et al. 2014), and thereby would mask 
the functions of proteins such as SRP-35, that evolved to increase the efficiency of vitamin A 
use. 
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CHAPTER 3 – GENERAL CONCLUSION AND 
PERSPECTIVES 
 
Diabetes and others metabolic diseases are linked to negative effects of skeletal muscle 
metabolism. The incidence of metabolic diseases is rising rapidly. Type 2 diabetes (mellitus) 
alone currently affects 190 million people worldwide and is predicted to increase to 300 
million by 2025. The effect of metabolic disease affecting skeletal muscle metabolism are 
very dramatic for the whole organism because of the important role played by muscle in 
removing  70-75 % of circulating glucose in an insulin-dependent manner. The skeletal 
muscle presents a complex machinery that induces muscle contraction and requires a high 
amount of energy consumed in form of ATP,; this triggers the AMPK pathway that induces 
glucose uptake into the cell and increasing the insulin sensitivity. The proper functioning of 
the skeletal muscle machinery during Excitation Contraction Coupling (ECC) affects the 
whole body energy consumption, by affecting AMPK and insulin.  
In the past few years our lab has focused on proteins relating to ECC, discovering new 
proteins involved in this process, or related to muscle function or metabolism. SRP-35, a 
protein present in the longitudinal sarcoplasmic reticulum, was discovered by our group 
several years ago; the present investigation reveals the role of SRP-35 in skeletal muscle 
metabolism. Transgenic mice overexpressing SRP-35 in their skeletal muscles were 
characterized biochemically and physiologically. The first important result obtained was the 
higher running capacity exhibited by the transgenic mice. This effect was not related to 
changes in fiber type composition or muscle force. Our results also show that SRP-35 is not 
directly involved in the ECC mechanism. This observation promoted us to further investigate 
the role of SRP-35 in skeletal muscle physiology. We thus discovered that the enhanced 
running capacity of SRP35TG mice was due to a metabolic effect on skeletal muscle, which 
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triggered the translocation of Glut4 to the sarcolemma and thus increased glucose uptake into 
the muscle, via the phosphorylation of AKTS473. 
This result was novel and exciting exposing the relationship between SRP-35 and muscle 
metabolism. After discovering the enhanced Glut4 translocation in muscles from SRP35TG 
mice, we discovered that this effect was mediated by a non-genomic effect of RARα and 
RARγ, inducing the stronger activation of PI3K and of mammalian target of rapamycin 
complex 2 (mTORC2) signaling pathways, which trigger the phosphorylation of AKTS473. 
Curiously, RA had been previously reported to activate in a non-genomic manner, the RARα 
and RARγ, triggering the activation of Ribosomal protein S6 kinase 3 (RSK2) and Mitogen- 
and stress-activated kinase 1 (MSK1) proteins, respectively (Tanoury et al., 2013), but a direct 
effect on mTORC2 pathway had not been clearly exposed..  
The signaling pathway downstream SRP-35 was elucidated in this study, showing that non-
genomic effects of atRA induce the activation of mTORC2 and finally the translocation of 
Glut4 to the sarcolemma. However, an important question still remains unanswered: how is 
SRP-35 activated physiologically? Which processes modulate the activation or inhibition of 
this enzyme? A hint to solve this question could be the observed synergetic effects between 
SRP-35/RA and insulin on AKTS473 phosphorylation. The fact that SRP-35 in the skeletal 
muscle is able to induce a higher glucose uptake on top of that induced by insulin alone 
exposes the possibility that SRP-35 could be under the control of an insulin-related pathway. 
Nevertheless, this theory needs to be confirmed by a deeper investigation on the upstream 
pathway leading to the activation of SRP-35.  
One important point to be considered for possible futures clinical treatments are the possible 
collateral effects of RA administration to the whole organism. For decades the teratogenic 
effect of RA on women of child-bearing potential had been known (David et al., 1988), and 
more recently a connection between RA and allergy development has been established 
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(Babina et al., 2017). On the other hand, overexpression of SRP-35 could offer an advantage 
over RA administration. We believe that due to the location of SRP-35 on the plasma 
membrane (same region of PI3K) of skeletal muscle, it is possible to form micro-domains 
where the RA concentration is higher and the effect on RARα/β and PI3K more specific. 
Increasing the levels of SRP-35 and skeletal muscle RA offers the advantage of increasing the 
sensitivity to insulin and avoids the collateral effects of the high concentration of 
pharmacological doses of RA, which cause unspecific and adverse effects for the whole 
organism. 
In conclusion SRP-35 may be a novel target for the treatment of metabolic syndromes 
characterized by a decreased sensitivity to insulin and decreased Glut4 translocation onto the 
plasma membrane. In order to evaluate if the higher expression of SRP-35 can rescue the 
phenotype of mice with type 2 diabetes futures studies based on crosses between SRP35TG 
mice and  Lep
ob/ob
 mice could be envisaged. These latter Lep negative mice are a commonly 
used model for obesity and emulate type 2 diabetes because of their obesity-induced 
hyperglycaemia. The results could give a hint as to the role of SRP-35 on the whole body 
metabolism; if this enzyme is able to rescue the phenotype of type 2 diabetes it would be a 
basic and important step for the future treatment of humans affected by metabolic disorders.  
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